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Abstract
Psychotic disorders can be variable in clinical presentation, and there may be differences by
sex. The objective of this thesis was to explore sex differences in the clinical presentation of
early psychosis in the context of primary care. Our systematic review and meta-analysis
found that men experienced more negative symptoms and had a higher prevalence of
substance use issues, whereas women experienced more depressive symptoms and had higher
functioning. Our electronic medical record analysis from primary care found that positive
symptoms and substance use were less prevalent in the medical records of women. We also
found that visits by women were more likely to be assigned a diagnosis of depression or
anxiety, personality disorder, psychological distress, and other mental or behavioural
disorders, and less likely to be assigned a diagnosis of substance use. Further research is
needed to better understand sex differences in clinical presentation in the primary care
context.

Keywords
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Summary for Lay Audience
Psychotic disorders are a group of severe mental illnesses that vary in clinical presentation,
which can include behaviours, symptoms, and course of illness. Psychosis is characterized by
impaired cognition or perception, which may present as positive symptoms (i.e.,
hallucinations, delusions), negative symptoms (i.e., reduction in language, motivation,
pleasure), disorganized thoughts and behaviour, and impairments in functioning. It is wellestablished that early intervention for psychotic disorders can help improve short- and longterm outcomes, and primary care is often the first point of contact for young people
experiencing first-episode or early psychosis. Prior research indicates that men and women
differ in their clinical presentation of early psychosis, but little is known about these
differences as they present to primary care. Given the vital role that family physicians and
primary care services play in the recognition of early psychosis, understanding how men and
women present differently in these settings is important. The overall aim of this thesis was to
explore sex differences in the clinical presentation of early psychosis in the context of
primary care. Our first study compiled findings from 35 studies examining sex differences in
symptoms of early psychosis, and found that men experienced more negative symptoms and
had a higher prevalence of substance use, whereas women experienced more depressive
symptoms and had higher functioning. All of the studies included in our review were from
specialized mental health services, and none examined sex differences in clinical presentation
from a primary care context. Our next study used health administrative data, linked with
electronic medical records from primary care in Ontario from 2005-2015. We found that one
year preceding the first diagnosis of psychotic disorder, positive symptoms and substance use
were less prevalent in the medical records of women. We also found that visits by women
were more likely to be assigned a diagnosis of depression or anxiety, personality disorder,
psychological distress, and other mental or behavioural disorders, and less likely to be
assigned a diagnosis of substance use. Larger studies that incorporate administrative and
patient-level data are needed to better understand sex differences in the clinical presentation
of early psychosis in the context of primary care.
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Chapter 1

1

Overview of Thesis

Psychotic disorders typically have an onset in adolescence or young-adulthood, and can
vary greatly in clinical presentation, including symptom profile and course of illness.1,2
The sex and gender of the person experiencing early psychosis may play a role in this
variability, which may arise from a complex interaction of biological and psychosocial
factors.3
Although there is evidence that young men and women with early psychosis differ in their
clinical presentation, there is limited research on how these differences present outside of
specialized settings. Given the important role that primary care and family physicians play
in early psychosis recognition and intervention, having a thorough understanding of these
sex differences is a clinical imperative.4
The overall goal of this thesis was to explore sex differences in the clinical presentation of
early psychosis in the context of primary care. Our systematic review and meta-analysis
(Chapter 3) synthesized previous literature on sex differences in symptoms of early
psychosis and found that men with early psychosis experienced more severe negative
symptoms (SMD=-0.15, 95%CI=-0.21, -0.09), whereas women experienced more severe
depressive symptoms (SMD=0.21, 95%CI=0.14,0.27) and had higher functioning
(SMD=0.16, 95%CI=0.10,0.23). We also found that women with early psychosis had a
lower prevalence of substance use issues than men (PR=0.65, 95%CI=0.61,0.69). All of
the studies included in our review were from specialized mental health services, and none
examined clinical presentation in the context of primary care. We then assessed sex
differences in the clinical presentation of early psychosis in a primary care setting using an
analysis of electronic medical records (EMR) in Ontario, Canada from 2005 to 2015
(Chapter 4). We found that one year preceding the first diagnosis of psychotic disorder,
positive symptoms (PR=0.76, 95%CI:0.58,0.98) and substance use (PR=0.54,
95%CI:0.40,0.72) were less prevalent in the medical records of women. We did not find
any other sex differences in symptoms at presentation to primary care. We also found that
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visits by women were more likely to be assigned a diagnosis of depression or anxiety
(PR=1.18, 95%CI:1.00,1.38), personality disorder (PR=5.49, 95%CI:1.22,24.62),
psychological distress (PR=11.29, 95%CI:1.23,103.91) and other mental or behavioural
disorders (PR=3.49, 95%CI:1.14,10.66), and less likely to be assigned a diagnosis of
substance use, alcohol use, or addiction (PR=0.33, 95%CI:0.13,0.87).

1.1 Role of the Student
In Chapter 2, detailed background information on psychotic disorders, primary care, and
sex and gender is provided. Chapter 3 is a systematic review and meta-analysis of prior
literature examining sex differences in symptoms of early psychosis. In Chapter 4, we
conducted an analysis using EMRs to examine sex differences in the clinical presentation
of early psychosis in a primary care setting. Chapter 5 synthesizes findings from the two
integrated articles and concludes the thesis.
I collaborated with Dr. Kelly Anderson to identify the research question and objectives for
this thesis, which were further refined through consultation with supervisory committee
members, Drs. Amanda L. Terry, and Suzanne Archie. I wrote all chapters of this thesis as
partial fulfillment of requirements for the Master of Science degree in Epidemiology and
Biostatistics. Feedback was incorporated from Drs. Anderson, Terry, and Archie.
I conducted the search for the systematic review, extracted data, and performed and
interpreted results of the meta-analysis (Chapter 3). Feedback for this chapter was also
sought from Jared Wootten who was a secondary reviewer, in addition to members of the
supervisory committee (Drs. Anderson, Terry, and Archie).
Chapter 4 used EMRs linked with health administrative data which was housed at ICES.
In collaboration with Dr. Anderson, the statistical methods for this chapter were developed.
Coding and cleaning of data, and interpretation of results were conducted with feedback
from Rebecca Rodrigues, Drs. Anderson, Terry, and Archie.
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Chapter 2
Background

2

2.1

Psychotic Disorders

This section will provide an overview of psychotic disorders and first-episode psychosis,
including the definition, prevalence, and impact, as well as risk factors for developing
psychosis.

2.1.1

Psychotic Disorders and First-Episode Psychosis

Psychotic disorders are a group of illnesses characterized by five domains of symptoms,
including hallucinations, delusions, disorganized thought, disorganized or abnormal motor
behaviour, and negative symptoms.5 Psychotic disorders affect about 24 million people
worldwide, and have an average lifetime prevalence of up to 1%.6 In Ontario alone, there
are nearly 5000 new cases of psychotic disorder every year.7 These disorders are chronic
and among the most debilitating illnesses worldwide,8 with about 9% of patients
experiencing lasting symptoms, and 43% experiencing symptoms that increase in severity,
with no periods of complete remission.2 There are many negative outcomes associated with
experiencing psychosis, including a shorter lifespan,3 and an increased risk of suicide,
substance abuse, homelessness, and violence compared to the general population.1 The first
onset of psychotic symptoms, termed first-episode psychosis (FEP), often occurs in
adolescence or young-adulthood, and can be variable in presentation.2 The level of insight
of patients experiencing FEP can also be quite variable, ranging from having full awareness
of symptoms and illness, to having no insight at all.2
In the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5),
psychotic disorders are distinguished from one another by the duration of symptoms,
symptom profile, the relationship between psychotic symptoms and mood disturbances,
and by cause.1 Psychotic disorders can be classified further as being affective or nonaffective, where affective psychoses are marked by severe mood disturbances. 9 Disorders
such as bipolar disorder, and major depression with psychotic features are considered to
be affective, whereas schizophrenia, schizoaffective disorder, and other schizophreniform
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disorders are considered to be non-affective.9 The age of onset of different psychotic
disorders may also differ accordingly. Symptom onset of common psychotic disorders –
such as schizophrenia, bipolar disorder, and depression with psychotic symptoms – often
occurs during adolescence and early adulthood, whereas the onset of delusional disorders
often occurs in middle age.1 The course of illness for psychotic disorders often evolve
through stages of premorbid, prodromal, syndromal, progressive, and chronic; however,
the duration, symptom presentation, and severity of the disorder can be unpredictable.1

2.1.2

Impact of FEP

Psychotic disorders have a great impact on both the person experiencing FEP, their families
and carers, and the healthcare system.2 Symptoms of psychosis, such as hallucinations,
delusions, or depression, can cause disruptions to the lives of people with FEP, resulting in
trauma, feelings of hopelessness, and an increased risk of suicide.2 Suicide is one of the
leading causes of death among people with schizophrenia, of which the risk is particularly
high within the first six years after symptom onset.2 The general population has a suicide
risk of about 0.5-1%, whereas the risk for people experiencing psychotic disorders is
estimated to be 15-25 fold higher.6 Additionally, people with FEP are more likely to have
substance use disorders, engage in violent behaviour,10 and use tobacco at some point in
their lives, putting their overall health at risk.2 The risk of mortality from cardiovascular
disease, respiratory disease, tuberculosis, cancer, and other infectious diseases is higher in
people with psychotic disorders relative to people from the general population.11
FEP often presents in adolescence, a formative time when young people are making a
transition to independence and establishing their own peer networks.2 The occurrence of
psychotic symptoms during this time can cause disruptions to this important development,
and makes it difficult to maintain social connections and to achieve educational and career
goals.2 Although there is a great need for social support during this time, behaviours of
people experiencing FEP (such as aggression or self-isolation), or the stigma surrounding
mental illness may cause friends to withdraw.2 Adolescents with FEP are also more likely
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to engage in risk-taking behaviours, such as unprotected sex or substance use, further
disrupting healthy relationships.2
In addition to the distress that experiencing the illness may cause, the treatment of
psychosis can also have a traumatic impact on the patient, including the experience of
involuntary hospitalizations, seclusions, and the use of restraints.2 In a Canadian study
conducted in 2004, patients with schizophrenia alone generated about 356,000 inmate days
in federal and provincial jails and prisons,6 which highlights the negative pathways many
people with psychotic disorders experience. Psychotic disorders also have an impact on the
families and carers of those experiencing the illness. The burden of care often falls on the
families of those affected, causing emotional distress related to the patient’s behaviour and
negative symptoms.2
The financial impact of psychotic disorders is profound, including the burden placed on
the Canadian healthcare system. In Canada, psychotic disorders account for 0.5% to 3.5%
of national healthcare expenses every year.6 Schizophrenia alone accounts for over 32,500
hospital stays and nearly 2.4 million days in the hospital annually, with a total cost
amounting in $2.02 billion per year.6 Furthermore, many people experiencing psychotic
disorders are unable to work, resulting in high rates of unemployment and demand for
government assistance.6

2.1.3

Risk Factors for Psychosis

A multitude of factors can increase the risk of developing psychotic disorders over the
lifetime, including both genetic and environmental factors.12 Genetic predisposition is
known to have an effect on the risk of developing a psychotic disorder, especially when
one or both parents have psychotic disorders.13 Prior research has indicated that rates of
psychotic disorders are 10 to 15 times higher among the siblings and parents of those with
psychotic disorders, compared to the general population.1
This genetic predisposition may be necessary, but not sufficient for a psychotic disorder to
develop; thus, the gene-environment interaction is most important to consider when
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examining the cause of such disorders.12 In the crucial developmental time before and
shortly after birth, the body may be exposed to a variety of environmental risk factors that
cause vulnerabilities to psychosis later in life.12 It was found that in combination with
genetic susceptibility to psychosis, obstetric complications or birth trauma contribute to the
causation of psychosis.12 Other factors, such as gestational infection, maternal stress,
diabetes, and smoking, and childhood environment may also contribute to increased
psychosis risk among offspring.12 Childhood trauma is an important and well-known risk
factor for developing a psychotic disorder, and can have an impact of symptoms in the
early course of illness.14
Later in life, factors that can be considered etiological may also modify the course of illness
after onset, such as drug abuse and dopamine desensitization.12 Additionally, both
migration and urbanicity have been identified as risk factors for psychotic disorders. A
meta-analysis found that immigrants had a significantly increased risk of schizophrenia
compared to native inhabitants, which may be due to excess stress and social adversity. 12
Prior research has indicated that urban and rural populations have different lifetime risks
for psychotic disorders, with exposure to urban residence increasing the risk for later
psychotic illness.15 It has been speculated that this difference may be due to urban
environmental factors that increases the vulnerability to psychosis.15

2.2

Primary Care

This section will provide an overview on primary care, including pathways to mental health
care, the impact of early intervention, and the role primary care and the family physician
plays in early psychosis.

2.2.1

Pathways to Mental Health Care

Prior research suggests that early intervention for psychotic disorders is a clinical
imperative to reducing patient suffering and improving clinical and functional outcomes
over the course of illness.16 This has led to a great interest in the ways people experiencing
psychosis access help, known as the pathway to care. The pathway to care for patients
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experiencing FEP can be quite variable and complex, including the use of services at
multiple levels of care.17 Emergency department visits and inpatient admissions are quite
common in these pathways.18 The help-seeking behaviour of the patient and/or family
members, accessibility of mental health services, and the response of health services at
each level of care all have an impact on the pathway to care.19 The process of help-seeking
for mental health is outlined by the Goldberg and Huxley model, in which there are five
levels with four “filters” between them deciding progression to the next level of care. 18
Factors that impact progression to the next level of care include patient characteristics,
clinical features, physician characteristics, and systemic barriers.18 The community is the
first level in the model where psychotic symptoms may emerge. At the second level, a
subset of these people with psychotic symptoms may seek help from a family physician
(FP), where some may be identified as having a psychotic disorder, comprising the third
level.18 Patients in this level may then be referred to mental health services for the fourth
level, and those that present to these services and are admitted to inpatient care comprise
the final level.18
The duration of untreated psychosis (DUP) has a significant impact on the course of illness
and long-term outcomes, and is affected by the pathway to care.17 Longer DUP is
associated with more severe positive and negative symptoms, reduced quality of life, and
a lower probability of entering disease remission.19 There are multiple factors that may act
as barriers on the pathway to care in FEP, prolonging the DUP. Treatment delays may be
due to affected individuals not seeking help early in their illness, or the difficulties faced
by health-professionals in identifying early signs and symptoms of psychosis.2 Factors that
may influence help-seeking of those experiencing FEP include self-stigma and lack of
knowledge surrounding symptom recognition and resources for psychotic disorders.17
These barriers can lead to treatment delays, resulting in a longer DUP and poor physical
and functional outcomes.20 It has been reported that family members or significant others
may play an important role in this initial help-seeking and maintenance of contact with
services.17 For persons experiencing FEP, family involvement can help decrease the
probability of involuntary and negative care pathways, such as involuntary hospitalizations
or involvement of police.17 Public education on the signs and symptoms of psychosis, as
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well as the resources available to those experiencing it is important for early recognition
and treatment of the illness.17

2.2.2

Impact of Early Intervention

Early psychosis intervention (EPI) programs focus on the detection of psychotic symptoms
and treatment in the early stages of illness for young people 14 to 35 years old.20 These
programs combine multiple interventions, such as pharmacologic and psychosocial, in a
comprehensive team-based model of care.21 There are over 50 EPI programs across
Ontario, in which most participate in a government-funded Early Psychosis Intervention
Ontario Network (EPION) to deliver standardized, high-quality care.21 The main goals of
EPI programs are to improve early access to services, promote recovery from the first
psychotic episode, and to reduce the risk of future epsiodes.22 Patients may be referred to
these services by family physicians, psychiatrists, or access these programs on their own
or with help from family. Short- and long-term outcomes of FEP can be improved by early
intervention, where distress associated with psychotic symptoms can be reduced and risk
of suicide is decreased.2 Prior literature has indicated that outcomes in the early stage of
illness can be predictive of illness severity in the later course of illness, emphasizing the
importance of receiving treatment as early as possible.2 Patient anxiety and distress from
FEP can be mitigated by a shorter DUP, which reduces the chance of relapse.2 Additionally,
EPI services may be more cost-effective than standard psychiatric care,23 largely due to its
impacts on use of high-cost acute mental health services. For example, an Ontario study
published in 2018 by Anderson et al. indicated that users of EPI services had more rapid
access to psychiatric services, fewer emergency department visits, and lower rates of
mortality for all causes.20 Users of these early intervention services, however; had higher
rates of hospitalizations and a lower rate of visits to primary care.20 In another study, it was
found that men with first onset psychotic disorder were more likely than women to be
represented in EPI services.24
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2.2.3

The Role of Primary Care

Although EPI programs have shown success and have provided a more optimistic outlook
for young people experiencing FEP, primary care is often the first point of contact, with
FPs playing an important role in the pathway to care and help-seeking.4,25 Prior research
has indicated that people experiencing FEP have a higher prevalence of primary care
contacts for mental, physical, and preventative health compared to those of the general
population.26 In Ontario, about 30% of young people with FEP are first diagnosed by a FP,
with an additional 30% receiving their diagnosis in secondary or tertiary care but having
contact with a FP for mental health reasons in the 6-month period before the first diagnosis
of psychosis.18
Evidence suggests that FPs may have difficulty identifying psychotic symptoms due to
symptom subtlety or a lack of knowledge on psychosis, resulting in multiple contact points
for FEP patients.19 To recognize a psychotic disorder, FPs must obtain knowledge of
family, medical, and cultural history of the patient, as these factors may provide clues to
diagnosis.4 Prior research on FPs’ knowledge of early psychosis found that FPs are likely
to identify more overt symptoms of psychosis such as hallucinations, delusions, and bizarre
behaviour, but under-identify less obvious symptoms such as functional decline.27 This is
important because evidence also suggests that patients with these insidious symptoms are
more likely to present to primary care.27 Treatment for FEP patients can be delayed if FPs
do not recognize more subtle symptoms of early psychosis, such as sleep disturbances,
depression, and social withdrawal, which may be attributed to other conditions or normal
adolescent behaviours.2 Having contact with a FP, however, may have a strong impact on
health service use patterns, reduce negative care pathways, and the DUP.28
Results from a population-based study in Quebec showed that people who were in contact
with a FP prior to a first diagnosis of psychotic disorder had almost three times more
contacts than those who were not.29 Additionally, individuals with primary care contact
had lower odds of contact with emergency services and lower odds of receiving a diagnosis
of psychotic disorder in the emergency department.29 Contacts with primary care were
associated with longer referral delays to specialized care, which may suggest difficulties
with symptom recognition or attempts made by the FP to manage psychotic symptoms
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within primary care.29 Taken together, these findings indicate that improvements in
primary care access may help to decrease the use of emergency services for early psychotic
disorders, although further training may be needed for FPs to recognize these symptoms
and efficiently refer patients to specialized care.29

2.3

The Role of Sex and Gender

This section will provide a summary of the definitions of sex and gender, how this relates
to psychosis, and the previous findings on sex and gender differences in early psychosis,
including incidence, age of onset, clinical presentation, and service-use.

2.3.1

Sex and Gender

Sex and gender are terms that are often entangled in research, with difficulties in separating
exactly what makes up a person’s sex or gender. The biological aspects of a person, such
as chromosomes, anatomy, genes, and hormones are constituted by sex, whereas gender is
used to describe the nonphysiological components, such as a social labels/roles and cultural
norms that are shaped by a person’s environment and experience.30 Gender may include
both the attributions of others, as well as for one’s self, which makes up gender identity.30
Aspects of both sex and gender can contribute to a person’s behaviour, with biological,
social, and psychological factors contributing to sex and gender differences.3
Sex and gender are vastly important in mental health research for understanding and
treating mental disorders, although there is criticism surrounding the dichotomous use of
sex and gender.31 There are many grey areas of sex and gender that binary definitions of
these variables are unable to address. Differences exist in the epidemiology of mental
disorders that can be attributed to sex.31 For example, hormone levels can play a role in the
clinical presentation of mental disorders and the effectiveness of medications, which differ
by sex.31 Furthermore, gender roles and social factors for men and women can help explain
differences in prognosis, risk factors, protective factors, and treatment outcomes of various
mental disorders.31 There is significant overlap between qualities of sex and gender, which
makes it difficult to disentangle them. Although both sex and gender play an important role
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in how mental illness is experienced, these variables are often neglected in mental health
research. This approach may result in biased findings, which can contribute to sub-optimal
care and an inadequate understanding of how men and women experience mental illness
differently.31 More specifically, an understanding of sex and gender differences in
psychotic disorders is important for early detection and intervention. Clinicians should
understand how to recognize psychotic disorders, and how to tailor interventions
specifically for men and women experiencing them.

2.3.2

Sex/Gender and Psychosis

Men and women experiencing FEP may differ in many ways, including in their age of
onset, clinical presentation, help-seeking, and service-use behaviours. These differences
may arise from a complex interaction of biological factors that make up sex, and
psychosocial factors that make up gender.32 Sex differences in early psychosis have been
previously studied, but findings are often inconsistent across studies and are limited to
patients specialized settings. Differences in treatment uptake and engagement may
contribute to the evolution of sex differences in early psychosis, and sex differences that
exist specifically in FEP remain a gap in the literature.
Prior studies have found that the lifetime risk of psychotic disorders is approximately the
same for men and women, suggesting that sex does not impact disease risk, but instead
modulates the timing of onset.33 The most replicated finding regarding sex differences in
early psychosis is the difference in age of onset.34 The first psychotic episode often occurs
earlier in life for men than women, with the average age of onset for men being 18 to 25
years, whereas women have an average age of onset of 25 to 35 years.34 The incidence
curves for age of onset also differ between men and women – evidence suggests that
women have two peaks of onset, with the first peak in adolescence or early adulthood, then
a second peak much later in life.34
These findings may be explained by the protective role that estrogens play in the
development of a psychotic disorder, called the sex hormone hypothesis. 35 This theory
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posits that from puberty to menopause, high estrogen levels protect women to some extent
from the onset of psychotic symptoms; and when these hormone levels decline the
protective factor is weakened.35 The lower levels of estrogen in these time frames may lead
to the presentation of psychotic symptoms, and a diagnosis of a psychotic disorder.33
Evidence also suggests that rates of relapse in women with psychotic disorders are reduced
at times of high estrogen levels, such as during pregnancy.36 Elevated estrogen levels may
also act as a protective factor against psychotic symptoms in men, but elevated testosterone
levels have been linked to more severe psychiatric symptoms.36 In contrast to the previous
finding on testosterone, it has also been found that men with psychotic disorders have
significantly lower levels of both estrogen and testosterone than healthy controls.36

2.3.3

Clinical Presentation

The clinical presentation of early psychosis can be quite variable, and sex or gender can
help explain some of this variability. The clinical presentation in men is often characterized
by a greater severity in negative and cognitive symptoms, and a higher frequency of
comorbid substance use, whereas the clinical presentation in women is often characterized
by the presence of affective symptoms.37 Women are also more likely to have higher levels
of functioning than men, particularly better social functioning and educational
attainment.38 This finding, however, may be partially explained by the difference in age of
onset between men and women.38 Because men tend to start experiencing psychotic
symptoms earlier in life than women, their social networks are not yet established, and
social functioning is therefore less favourable.38 Although women may function better than
men at baseline, some studies have also found that suicidal behaviours are more common
in women than men.38–40
Due to the differences in symptoms experienced by men and women, women are more
frequently diagnosed with schizoaffective disorder or other non-schizophrenia diagnoses,37
whereas men are more frequently diagnosed with schizophrenia and schizotypal disorder.38
Furthermore, women with emerging psychosis are likely to be initially misdiagnosed as
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having a personality disorder, anxiety, post-traumatic stress disorder (PTSD), or
depression.37
Although it is often thought that women with psychotic disorders experience a milder
course of illness than men over the lifetime, recent findings suggest that the recovery rates
are similar among men and women.37 Furthermore, premorbid and baseline characteristics
may appear to be better in women in the first three years of illness onset, but the clinical
and functional outcomes in both sexes seem to balance after an average period of ten
years.37 Women are often underrepresented in in studies, and not all studies analyze results
by sex.37 This could reflect an underestimation of illness severity in women and highlight
the need to better understand how men and women are differently affected by psychotic
disorders.

2.3.4

Help-Seeking and Service-Use

Help-seeking behaviours differ among men and women, with a previous study from
Fridgen and colleagues finding that among people experiencing FEP, women requested
help almost twice as often as men.25 This may be explained by a greater willingness of
women to trust health professionals, or a greater openness toward mental health care.25 As
psychotic disorders often first present in adolescence, it is also important to consider factors
that contribute to help-seeking and service-use during this time. In a study conducted on
help-seeking for depression in early adolescents, it was found that older age and female
gender contributes to the promotion of help-seeking behaviour.41 Furthermore, it was found
that recognition of stress, openness, recognition of help from adults, higher household
income, parental divorce, and previous parental service use promoted help-seeking
behaviours in adolescents.41 It was hypothesized that gender norms surrounding problem
solving between boys and girls inhibits boys from engaging in help-seeking behaviour.
These findings may be applicable to adolescent girls and boys experiencing psychosis and
may account for some of the sex differences seen in service-use. Although women may be
more likely to seek help for mental health reasons than men, evidence suggests that the
DUP may be longer in women compared to men.37 This could be explained by misdiagnosis
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of women with FEP, delaying the initiation of antipsychotic treatment.37 In regards to sex
differences in service-use, a Canadian study from 2004 found that men with schizophrenia
had more hospitalizations than females in both acute and non-acute hospitals.6 Further
research is needed to fully understand sex differences in help-seeking and service-use for
young people experiencing FEP.

2.4

Study Rationale and Objectives

Previous findings indicate that sex and gender differences in symptoms of psychosis exist,
and that these differences are also present in the early stages or the first episode of
psychosis.32,34 There has been extensive research conducted on sex differences in
symptoms of psychotic disorders, particularly schizophrenia, and how these differences
present to specialized care settings.14,42–44 The role that primary care plays in the
identification and treatment of psychotic disorders is well-established,19,26,29 but many
aspects of psychosis in primary care remain unexplored. There is a paucity of research on
how symptoms of early psychosis present in the primary care context, and how men and
women differ in this clinical presentation.

2.4.1

Study Objectives

There is a need to evaluate sex differences in symptoms of early psychosis in the context
of primary care. The overall objective of this thesis was to explore sex differences in the
clinical presentation of early psychosis in the context of primary care. This was achieved
through a systematic review and meta-analysis of the prior literature (Chapter 3) to identify
what was already known about sex and gender differences in symptoms of early psychosis.
Additionally, an analysis of the electronic medical records of FEP cases in primary care
was conducted (Chapter 4) to identify and describe the sex differences in symptoms of
early psychosis in a primary care context. To meet these objectives, our thesis aimed to
answer the following questions:
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1. Is there a significant difference between early psychosis symptoms for men
and women? (Chapter 3)
2. What are the differences in clinical presentation (i.e., signs and symptoms)
of early psychosis between men and women in a primary care context?
(Chapter 4)
3. What are the sex differences in diagnoses made by the family physician for
mental health related encounters one year prior to the first diagnosis of a
psychotic disorder? (Chapter 4)
4. Do clinical and sociodemographic factors affect these sex differences in
clinical presentation and diagnoses? (Chapter 4)
We hypothesized that men would present with more negative symptoms and substance use
than women, whereas women would present with more general symptoms and display
higher levels of functioning than men. We hope that findings from this study will facilitate
a greater awareness of psychotic symptoms at the primary care level and help to clarify
how men and women differ in these symptoms, as well as how sex differences in clinical
presentation may differ from acute care settings. This information will assist FPs in their
ability to detect psychotic disorders and to facilitate early intervention. In turn, clinical and
functional outcomes of young people experiencing early psychosis in Ontario may be
improved.
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Chapter 3

3

Sex and Gender Differences in Symptoms of Early
Psychosis: A Systematic Review and Meta-Analysis

3.1 Abstract
Background: First-episode psychosis (FEP) can be quite variable in clinical presentation,
and both sex and gender may account for some of this variability. Prior literature on sex or
gender differences in symptoms of psychosis have been inconclusive, and a comprehensive
summary of evidence on the early course of illness is lacking. The objective of this study
was to conduct a systematic review and meta-analysis of the literature to summarize prior
evidence on the sex and gender differences in the symptoms of early psychosis. Methods:
We conducted an electronic database search (MEDLINE, Scopus, PsycINFO and
CINAHL) from 1990 to present to identify quantitative studies focused on sex or gender
differences in the symptoms of early psychosis. We used random effects models to
compute pooled standardized mean differences (SMD) and risk ratios (RR), with 95%
confidence intervals (CI), for a range of symptoms. Results: Thirty-five studies met the
inclusion criteria for the systematic review, and 30 studies were included in the metaanalysis. All studies examined sex differences. Men experienced more severe negative
symptoms (SMD=-0.15, 95%CI=-0.21,-0.09), whereas women experienced more severe
depressive symptoms (SMD=0.21, 95%CI=0.14,0.27) and had higher functioning
(SMD=0.16, 95%CI=0.10,0.23). Women also had a lower prevalence of substance use
issues (RR=0.65, 95%CI=0.61,0.69). Conclusions: Symptoms of early psychosis varied
between men and women; however, we were limited in our ability to differentiate between
biological sex and gender factors. These findings may help to inform early detection and
intervention efforts to better account for sex and gender differences in early psychosis
presentation.
Keywords Sex differences; Psychosis; Symptoms; First-episode psychosis
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3.2 Background
Psychotic disorders are characterized by dysfunction in cognition or perception,1 which
may include the presence of positive symptoms (i.e. hallucinations, delusions), negative
symptoms (i.e. anhedonia, social withdrawal), disorganized thoughts and behaviour, and
impairments in functioning.45 The symptoms of psychosis exist on a continuum with
normal mental states, with each person’s clinical presentation varying in severity along this
continuum, defined by the level, number, and duration of symptoms.5
The first occurrence of psychotic symptoms, known as first-episode psychosis (FEP),
usually presents in adolescence or early adulthood,2 and the clinical presentation at onset
may be quite variable.34 Early intervention for psychotic disorders can optimize the course
of illness and clinical prognosis of those affected, as a shorter duration of untreated
psychosis is associated with a lower number of hospitalizations and a reduced risk of
relapse.45 In order for the duration of untreated psychosis to be minimized, clinicians must
be able to identify psychotic symptoms in their varying presentations.
The sex and gender of a person experiencing FEP or early psychosis may account for some
of the heterogeneity in clinical presentation, with respect to age of onset, symptom profile,
level of functioning, and course of illness.34 Sex is comprised of the biological aspects of
a person, such as chromosomes, anatomy, genes, and hormones; whereas gender is used to
describe the nonphysiological components of a person, such as social labels/roles and
cultural norms that are shaped by a person’s environment and experience.30 Differences in
age of onset of FEP have been well-documented in the literature, with the average age of
onset of psychotic symptoms being higher in women than in men.34 This imbalance has
been attributed to the difference in timing of puberty between boys and girls, and estradiol
being a protective hormone for psychotic disorders in both men and women.46 This may
also explain the second peak in psychosis incidence for women around menopause, when
levels of these hormones decrease.47 Similarly, some studies have found that estrogen may
modulate the severity of psychotic symptoms, resulting in a lower disease severity in
women.48 Other studies have indicated that men experiencing psychotic symptoms have
lower estradiol and testosterone levels compared to healthy controls, further indicating the
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protective effect of estradiol in men.36,47 Gender norms and behaviours may also play a role
in symptom variation between males and females with psychotic disorders. For example,
women tend to be more socially integrated, whereas men’s social behaviours are more
passive and dysfunctional.49 In general, women tend to be more introspective toward their
mental health, and are more willing to seek help than men.25,50 These gender roles may
contribute to differential help-seeking behaviours between men and women, and
willingness to comply with treatment plans.49 Adolescent girls are more likely to seek help
on their own, while the parents of boys are more likely to seek help for them.51 This
behaviour carries over into adulthood, where women seek help for mental health reasons
almost twice as often as men.25 Men are also more likely to engage in substance use than
women, and gender-related factors may have an impact on this difference.49,52 For example,
there is more societal acceptance surrounding men that use cannabis than women,52 and
peer pressure to use cannabis is elevated in men compared to women.53,54 These factors
may influence the risk of psychotic disorders and impact clinical presentation.55 Sex and
gender are often entangled in research, and it is difficult to differentiate the pathways
between biological and social aspects that lead to differences in clinical presentation.
Sex and gender differences in symptoms of psychotic disorders have been studied
extensively, although findings are often inconsistent across studies. It has been reported
that men tend to experience more negative symptoms – including apathy, poverty of speech
and thought, and social withdrawal – whereas affective symptoms, such as depression and
mania, tend to occur more frequently in women.32 Additionally, men often experience more
social isolation, have poorer social functioning, and have more substance use than women
with psychotic disorders.32 Conversely, many other studies have concluded that there were
no significant differences in symptoms by sex or gender.34
Prior literature on sex or gender differences in the symptoms of psychotic disorders are
inconclusive, and have been limited by small sample sizes and methodological differences
between studies.32 A comprehensive summary of the evidence base on symptoms in the
early course of illness is lacking. The aim of this study was to systematically review the
literature on sex or gender differences in symptoms of early psychosis, and to quantify any
observed differences. The findings from this systematic review and meta-analysis may be
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used to profile the clinical presentation of FEP or early psychosis more accurately by sex
and gender to support early identification and intervention for psychotic disorders.

3.3 Methods
This systematic review follows the Preferred Reporting Items for Systematic Reviews and
Meta-Analyses (PRISMA 2020) reporting guidelines (Appendix 3A).56

3.3.1

Search Strategy and Study Selection

We searched four electronic databases – including Medline (ProQuest), Scopus, PsycINFO
and Cumulative Index to Nursing and Allied Health Literature (CINAHL) – for studies
related to sex or gender differences in symptoms of early psychosis or FEP. No limits were
placed on language, and we restricted the search to studies published after 1990 to represent
the current standard of care for treating psychosis.57 The specific search terms used for
each database can be found in Appendix 3B. Results from the search were imported into
the Covidence systematic review management platform (www.covidence.org) for article
screening. Grey literature searching was done using Google Scholar and Open Grey, and
unpublished work was searched in a pre-print database (medRxiv). Additional studies were
identified using forward and backward citation tracing of included articles.
We included studies if the sample consisted of first episode or early psychosis patients,
defined by all definitions of FEP as reported by the original studies, which can vary across
studies.58 Both affective and non-affective psychotic disorders were included, and no
restrictions were placed on the age of the sample. To be included in the review, studies
must have compared symptoms of psychosis or other features of clinical presentation by
sex or gender. We included any type of observational study that provided quantitative
results, or interventional studies that provided baseline symptom differences by sex or
gender. We excluded studies that included people with chronic psychotic disorders, nonpsychotic mental disorders, and ultra-high risk (UHR), clinical high-risk patients (CHR),
or prodromal patients. Other experimental or interventional studies, case-reports, caseseries, and qualitative studies were also excluded from the review. See Appendix 3C for
full inclusion and exclusion criteria.
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Level one title and abstract screening was performed by one reviewer (BC) in Covidence,
and level two full-text screening was performed by two independent reviewers (BC, JW),
applying the inclusion and exclusion criteria. Reasons for exclusion were recorded in
Covidence, and discrepancies between reviewers were handled by group discussion and
consensus.

3.3.2

Data Extraction and Risk of Bias Assessment

Data extraction was completed by one reviewer, then verified by a second independent
reviewer, using a form created and pilot-tested in Microsoft Excel using the Cochrane
guidelines.59 Three main categories for extraction were: study characteristics (e.g., study
design, source of sample) sample characteristics (e.g., sample size, mean age of sample),
and study findings (e.g., symptom scores by sex).
Risk of bias of each study was assessed by two independent reviewers using the “Tools to
Assess Risk of Bias in Cohort Studies” by the CLARITY group at McMaster University,60
which fit the needs of this review topic. To ensure comprehensive assessment of other noncohort studies, two items from the “Risk of Bias for Cross-Sectional Surveys” created by
the CLARITY group were also used. The domains assessed in the risk of bias tools
included: representativeness of the sample, selection of cohorts, assessment of
exposure/outcome, measurement and analysis of confounding factors, and missing data.
For each study, each item was rated as low, intermediate, or high risk of bias.

3.3.3

Data Synthesis

We synthesized the data qualitatively by summarizing sex/gender differences in the most
common symptoms of psychosis across the included studies.
Stata version 17.0 61 was used to conduct all meta-analyses. The metan command was used
with random effect models to account for study heterogeneity.62 Meta-analyses were
conducted for each symptom (with subgroup analyses by symptom measurement tool),
which included each study that reported means and standard deviations on the symptom of
interest. Studies that reported medians and interquartile ranges were not included in the
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meta-analysis. We computed the standardized mean difference (SMD) in symptoms
between men and women, with 95% confidence intervals (CI). Statistical heterogeneity
was assessed using the I2 statistic, where a value of less than 25% is considered to be low
heterogeneity, 50% is considered to be moderate heterogeneity, and greater than 75% is
considered to be high heterogeneity.62 For symptoms where SMD was not applicable (i.e.
binary variable), prevalence ratios (PR) for cross-sectional studies and risk ratios (RR) for
cohort studies were pooled.63

3.4
3.4.1

Results
Study Selection and Characteristics

Our electronic database search yielded 4,955 studies published after 1990. Through a
further search of pre-print databases, grey literature databases, and forward and backward
citation tracing, 13 additional studies were obtained. After removing duplicates, 4,436
records were screened based on title and abstract, in which we excluded 4,120 studies. The
remaining 316 studies underwent full-text screening by two reviewers. Of those, 35 studies
were retained for qualitative synthesis, and 30 studies included data suitable for a metaanalysis. Of the studies chosen for inclusion in the systematic review and meta-analysis,
all looked at the sex of participants as a main exposure, with no studies measuring gender.
The PRISMA diagram outlining numbers and reasons for exclusion is presented in Figure
3.1.
Table 3.1 shows the study and sample characteristics of the 35 included studies. Seven
studies were published in North America, 18 studies were published in Europe, one study
was published in Africa, five studies were published in Asia, and the remaining four studies
were published in Australia. Most included studies used either a cohort (n=25) or crosssectional (n=7) design, and most (n=18) recruited the sample from early psychosis
intervention services. Other studies recruited their samples from other outpatient mental
health services (n=3), inpatient services (n=9), a combination of inpatient and outpatient
sources (n=3), or used health administrative data (n=2). The sample size of included studies
ranged from 39 to 3,350 patients, with males comprising a median of 64.2% (range = 33%-
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80%) of the sample across studies. Most studies used standardized interviews to establish
a diagnosis of psychotic disorder, with the majority using DSM-IV or ICD-10 diagnostic
criteria.

Listed

diagnoses

included

schizophrenia,

schizoaffective

disorder,

schizophreniform disorder, drug-induced psychosis, bipolar disorder, major depressive
disorder with psychotic features, affective psychosis with mood-incongruent delusions,
brief psychotic episode, non-affective psychosis, and psychotic disorder not otherwise
specified. A summary of the tools used to measure symptoms in each study can be found
in Appendix 3D.
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Figure 3.1: PRISMA diagram of study identification and selection for systematic
review and meta-analysis
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Table 3.1: Summary of study/sample characteristics of included studies (n=35)
Study ID, Author

Year

Country

1. Arnold et al. 64

2002

2. Arranz et al.43

2020

United
States
Spain

3. Austad et al.40

2015

4. Ayesa-Arriola et
al.65
5. Barajas et al.66

inpatient

Sample
Size
180

Age
Range
18-45

cohort

inpatient

204

18-35

Norway

cohort

outpatient-EPI

246

15-65

2014

Spain

cohort

outpatient-EPI

161

15-60

2010

Spain

cohort

outpatient-all

53

7-65

SCZ, SFD, SCZA, BPD,
DD, AP, PDN, DIP
BPD, SFD, SCZ, SCZA,
PDN
PDN

6. Bertani et al.67

2012

Italy

outpatient-all

397

15-54

NAP, AP

7. Buck et al.68

2020

Canada

crosssectional
cohort

outpatient-EPI

435

18-35

8. Caton et al.42

2014

cohort

inpatient

217

17-45

9. Chang et al.39

2011

United
States
China

SCZ, SCZA, NAP, DD,
BPD, PDN, BD, MDD
PDN

cohort

outpatient-EPI

700

18-55

SCZ, AP, SCZA, PDN

>3 years from first episode

10. Chen et al.69

2018

China

outpatient-all

110

18-35

SCZ

No past antipsychotic treatment

11.Cocchi et al.70

2014

Italy

outpatient-EPI

152

17-30

SCZ

DUP <24 months

12. Cotton et al.44

2009

Australia

casecontrol
casecontrol
cohort

outpatient-EPI

661

15-29

SCZA, NAP

First treated psychotic episode

13. Dama et al.71

2019

Canada

cohort

outpatient-EPI

569

14-35

SCZA, NAP

No past antipsychotic treatment for >1 month

14. Danaher et al.72

2018

Australia

outpatient-EPI

134

15-25

2016

Spain

outpatient-EPI

79

18-35

SCZ, SFD, SCZA, BPD,
DD, AP, PDN
SCZ, SFD, BD, PDN

>6 months remaining in EPI treatment

15. Garcia et al.73
16. Heitz et al.74

2016

Switzerland

crosssectional
casecontrol
cohort

outpatient-EPI

89

18+

PDN

17. Hui et al.75

2016

China

cohort

360

26-55

2008

Denmark

cohort

population-based
survey
outpatient-EPI

269

16-35

SCZ, DD, SFD, BPD, PDN,
SCZA
PDN

Attenuated or brief limited intermittent psychotic
symptoms
<1 year antipsychotic treatment

2018

China

cohort

outpatient-EPI

39

16-45

SCZ

18. Køster et al.49
19. Lang et al.

76

Study
Design
cohort

Sample Source

Diagnoses Included

Definition of FEP/ Early Psychosis

SCZ, SCZA, NAP, BD,
MDD
N/A

Presence of at least one psychotic symptom
Admitted to inpatient unit for first time for FEP with
psychotic symptoms of <1 year duration
<12 weeks of antipsychotic treatment,
No prior antipsychotic treatment
Two or more psychotic symptoms for <1 year, <6
months since first contact
Presence of 1+ positive symptoms or 2+ negative
symptoms
No past antipsychotic treatment for >1 month
Presence of 1+ psychotic symptoms

<3 years since onset of illness

First psychotic episode
Experiencing acute psychotic episode

Notes: SCZ = Schizophrenia, SCZA = Schizoaffective disorder, NAP = non-affective psychoses, BD = bipolar disorder, MDD = major depressive disorder, SFD= Schizophreniform disorder, BPD = brief psychotic disorder, DD =
delusional disorder, AP = affective psychosis, PDN = psychotic disorder not otherwise specified, DIP = drug-induced psychosis, MD = mood disorders, AD = anxiety disorders, PD = personality disorders, FEPM= first episode
psychotic mania. Symptoms were measured at index for all included studies.
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Table 3.1 con’t: Summary of study/sample characteristics of included studies (n=35)
Study ID, Author

Year

Country

Sample Source

Canada

Study
Design
cohort

Age
Range
N/A

Diagnoses Included

Definition of FEP/ Early Psychosis

outpatient-EPI

Sample
Size
88

20. Malla et al.77

2002

SCZ, SFD, BD, PDN

>1 week psychotic symptoms

2006

Zambia

cohort

inpatient

160

12-86

SCZ, SFD, BD, PDN

UK

cohort

inpatient

166

16-60

2020

Canada

outpatient-EPI

171

18-35

24. Preston et al.81

2002

Australia

outpatient-EPI

44

15-35

25. Pruessner et al.82

2019

Canada

crosssectional
crosssectional
cohort

SCZ, SFD, SCZA,
AP, NAP
SCZ, SCZA, DD,
SFD, DIP, PDN
SCZ, SFD, PDN

Diagnosis of psychotic disorder by DSM-IV, positive on
Psychosis Screening Questionnaire
Presence of at least one positive symptom

22. Navarro et a. 79

1996

23. Penney et al.80

outpatient-EPI

210

14-35

AP, NAP

Diagnosis of FEP by Operational Checklist for Psychotic
Illness and Affective Illness
<1 month antipsychotic treatment

26. Rapado-Castro et
al. 83
27. Segarra et al.84

2015

Spain

cohort

in/outpatient

61

7-17

SCZ, BD, PDN

<6 months from onset

2012

Spain

cohort

in/outpatient

231

15-65

SCZ, SFD

28. Suhail &
Chaudry85
29. Talonen et al.86

2006

Pakistan

inpatient

140

16-40

SCZ

2017

Finland

crosssectional
cohort

Presence of positive symptoms, no prior antipsychotic
treatment
First admission, >4 weeks duration

inpatient

106

13-17

30. Vila-Badia et al.87

2020

Spain

inpatient

70

13-55

31. Irving et al.88

2021

UK

16-65

2013

Australia

registry/admin
data
outpatient-EPI

3350

32. Cotton et al8.6

crosssectional
crosssectional
cohort

DIP, SCZ, MD, AD,
PD
PDN

118

15-29

BD, DIP, SCZ,
SCZA, PDN
FEPM

33. Häfner et al.90

1992

Germany

cohort

inpatient

267

12-59

SCZ

First admission for psychotic episode

34. GonzaáezRodriguez et al.91
35. Thorup et al.38

2014

Switzerland

cohort

outpatient-EPI

87

18+

FEP

2007

Denmark

cohort

In/outpatient

578

18-45

SCZ, DD, SCZA,
PDN

FEP diagnosis by the Basel Screening Instrument for
Psychosis, symptoms at least several times a week
<12 weeks antipsychotic treatment

21. Mbewe et al.

78

<6 months from onset

First diagnosis of psychotic disorder
Presenting with psychotic symptoms (positive, negative,
disorganized) for at least one week and <5 years
<1 year from onset
First psychotic episode

Notes: SCZ = Schizophrenia, SCZA = Schizoaffective disorder, NAP = non-affective psychoses, BD = bipolar disorder, MDD = major depressive disorder, SFD= Schizophreniform disorder, BPD = brief psychotic disorder, DD =
delusional disorder, AP = affective psychosis, PDN = psychotic disorder not otherwise specified, DIP = drug-induced psychosis, MD = mood disorders, AD = anxiety disorders, PD = personality disorders, FEPM= first episode
psychotic mania. Symptoms were measured at index for all included studies.
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3.4.2

Risk of Bias

Figure 3.2 presents the findings from the risk of bias assessment. Representativeness of the
source population was a concern in the majority of included studies, as only 37% of studies
had a low risk of bias on this domain. Studies with a low risk of bias recruited samples
though early psychosis intervention clinics or other mental health services. Small sample
sizes – often consisting of many more males than females – accounted for a large portion
of this intermediate and high risk across studies.
Measurement and adjustment for confounding factors in the analysis was another common
risk of bias, with only half of studies having a low risk of bias in these domains
(measurement = 49%; adjustment = 49%). There is potential for other factors, such as
ethnicity or age of participants, to bias the relationship between sex and clinical
presentation, although these factors were not mentioned or accounted for in many analyses.
Most studies had a low risk of bias in the domains of selection of exposed and non-exposed
cohorts (77%), assessment of exposures (91%), and assessment of outcomes (86%), with
the latter largely due to the use of standardized interviews and measures to obtain diagnoses
and symptoms. There was also a low risk of bias due to missing data, with 83% of studies
having a low risk of bias.

27

Figure 3.2: Summary of findings from the risk of bias assessment

Figures generated from https://mcguinlu.shinyapps.io/robvis/
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3.4.3

Summary of Findings

The results from individual studies can be found in Appendix 3E-3I and are summarized
in Table 3.2. Mean scores and standard deviations on each symptom scale were recorded
from each study for both males and females. A wide range of psychotic symptoms were
reported across the included studies, and the most common symptoms were compiled.
Positive symptoms – such as hallucinations, delusions, and paranoia – and negative
symptoms, such as apathy, poverty of speech/thought, and emotional/social withdrawal,
were two of the main categories of symptoms recorded. Other common categories of
symptoms assessed in the included studies were depression, general psychopathology
symptoms, functioning, and substance use (alcohol and drug use). The results from the
meta-analysis can be found in Figure 3.3.
Among the included studies that looked at positive symptoms of psychosis (n=31), 16
found more severe positive symptoms among men, 8 studies found more severe positive
symptoms among women, and the remaining 7 studies found no differences between men
and women (Appendix 3D). Twenty-one studies included data on positive symptom
severity that were suitable for a meta-analysis (Figure 3.3, Appendix 3J). The overall SMD
for positive symptoms was -0.03 (95%CI: -0.09, 0.03; I2=46.8%), which suggests no
difference in positive symptoms between men and women, and the findings were largely
consistent across measurement tools.
Thirty studies looked at negative symptoms of psychosis, and 25 studies found more severe
negative symptoms among men, while only one study reported more severe negative
symptoms among women, and four reported no difference between men and women
(Appendix 3D). Twenty-one studies included data on negative symptoms suitable for a
meta-analysis (Figure 3.3, Appendix 3K), in which the overall SMD was found to be -0.15
(95%CI: -0.21, -0.09, I2=50.9%), indicating that women experience significantly lower
negative symptom severity than men. Consistent with the findings from the meta-analysis
on positive symptoms, the findings were consistent across measurement tools.
Depressive symptoms were assessed in 20 of the included studies and of those, 14 found
more severe depressive symptoms in women, three studies found more severe depressive
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symptoms in men, and three studies found no difference between men and women
(Appendix 3E). Twelve studies included data on depressive symptoms suitable for metaanalysis, (Figure 3.3, Appendix 3L) in which the overall SMD was 0.21 (95%CI: 0.14,
0.27, I2=76.1%), indicating that women experience significantly more severe depressive
symptoms than men.
Symptoms of general psychopathology were assessed in 14 of the included studies
(Appendix 3F), in which six studies found more severe symptoms among men, four studies
found more severe symptoms among women, and four studies found no difference between
men and women. Twelve studies were included in the general psychopathology metaanalysis (Figure 3.3, Appendix 3M), where the overall effect was found to be

-0.06

(95%CI: -0.16, 0.04, I2=50.0%), suggesting no significant difference between men and
women.
Sixteen included studies assessed overall level of functioning (Appendix 3G), and of these,
13 studies reported that women had higher levels of functioning, two studies reported that
men had higher levels of functioning, and one study reported that men and women had
similar levels of functioning. Fifteen studies provided data suitable for a meta-analysis
(Figure 3.3, Appendix 3N), in which the pooled effect was 0.16 (95%CI: 0.10, 0.23,
I2=68.5%), suggesting that women had significantly higher levels of functioning than men.
The findings from studies looking at substance use can be found in Appendix 3H. Five
studies assessed overall substance use among their sample, with all studies reporting a
higher prevalence of substance use among men than women. Six studies assessed alcohol
use among their sample, with four reporting a higher prevalence of alcohol use among men
compared to women. Ten studies assessed drug use among their sample, and all reported a
higher prevalence of drug use among men compared to women. Thirteen studies were used
in the meta-analysis (Figure 3.3, Appendix 3O), in which the pooled risk ratio was 0.65
(95%CI: 0.61, 0.69, I2=0.0%), suggesting that women had a significantly lower risk of
substance use compared to men.
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Table 3.2: Main findings by symptom category across studies
Symptom Category

Number of Studies

Overall Trend Direction

Positive

31

16/31 more severe symptoms
in men

Negative

30

25/30 more severe symptoms
in men

Depression

20

14/20 more severe symptoms
in women

Psychopathology

14

6/14 more severe symptoms
in men

Functioning

16

13/16 higher functioning in
women

Substance Use (combined

5

5/5 higher prevalence in men

Alcohol Use

6

4/6 higher prevalence in men

Drug Use

10

10/10 higher prevalence in

alcohol and drug use)

men

31

Figure 3.3: Results from meta-analysis by symptom measure, with subgroup analysis
by measurement tool (n=30)

Notes: SMD = Standardized Mean Difference, PANSS = Positive and Negative Syndrome Scale, SAPS = Scale for the Assessment of Positive Symptoms, CGI-S/BP
= The Clinical Global Impression-Severity Scale/ Bipolar, BPRS = Brief Psychiatric Rating Scale, SANS = Scale for the Assessment of Negative Symptoms, CDSS =
The Calgary Depression Scale, FCQ = Frankfurt Complaint Questionnaire, GAF = Global Assessment of Functioning Scale, SOFAS = Social and Occupational
Functioning Assessment Scale

32

3.5
3.5.1

Discussion
Summary of Evidence

The findings from our systematic review and meta-analysis suggest that men with FEP or
early psychosis experience greater severity of negative symptoms and a higher likelihood
of substance use, whereas women experience greater severity of depressive symptoms and
a higher level of functioning. Symptom severity is often characterized by the level of
interference with day-to-day functioning. Less severe symptoms interfere little in day-today functioning, while the most severe symptoms drastically interfere with functioning,
with the possible need of supervision and assistance.92 We did not find differences between
men and women in positive symptoms or symptoms of general psychopathology. These
findings on sex differences in the symptoms of early psychosis are consistent with findings
from previous reviews on sex differences in chronic schizophrenia.93,94
Prior literature suggests that men have a higher incidence of psychotic disorders than
women,34 which may account for the gender distributions observed in the study samples.
Ochoa and colleagues discussed the differences in diagnoses of psychotic disorders
between men and women, and alluded to the idea that although more cases of psychosis
are recorded among men, this difference may be due to difficulties detecting the illness
among women.34 The average age of onset for women with psychotic disorders tends to be
later in life than men, which can be explained by the second peak in onset that women
experience post-menopause, raising the group mean for women.32,34,95 It is still largely
unknown why men may present with psychotic symptoms earlier in life than women, but
some hypothesize that higher cannabis consumption in men,32 or protective hormones in
women 96 may account for this difference.
Previous research on sex differences in the symptoms of psychosis have been well
documented, however; it is less clear whether sex differences are present at the initial
presentation for psychotic disorders or emerge later in the course of illness due to
differences in service engagement and treatment adherence. It is generally acknowledged
that men present with more severe negative symptoms than women, whereas women
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display more severe affective symptoms, such as depression and lack of energy.32 This
systematic review and meta-analysis clarifies these differences and provides evidence for
sex differences in the early course of illness. It was found that men experienced more severe
negative symptoms, such as apathy or social/emotional withdrawal, than women, whereas
we did not find evidence of sex differences in positive symptoms, such as hallucinations
and delusions. Additionally, we found that women experienced more severe depressive or
affective symptoms than men. These findings align with a prior literature review on gender
differences in schizophrenia symptoms, which found more severe negative symptoms in
men, more severe affective symptoms in women, but inconclusive findings on positive
symptoms.34 Lower symptom severity in women supports our finding that women have
higher levels of functioning than men, however; further research is needed to confirm this
relationship.
The studies included in this review focused on differences in clinical presentation of
psychosis in men and women through the lens of biological sex; however, it is important
to highlight the role that gender could play in this relationship. Although examining these
differences in terms of sex may provide information regarding the biological influences on
psychosis presentation, examining these differences in terms of social implications of sex,
referred to as gender may provide information regarding how factors related to
socialization influence the presentation of psychosis. We did not identify any studies
focused on how gender may impact psychosis presentation, but these influences could stem
from differences in patterns of behaviour, thinking, and feeling between the genders.49 For
example, men are more likely to smoke cannabis, and women may exhibit more social
behaviours and willingness to accept help.49 Some of the findings from the current review
could also be explained through a gender lens, for example where men have higher rates
of substance use and women have higher levels of functioning. Future research on the
relative contributions of sex and gender to differences in clinical presentation in FEP or
early psychosis is warranted.
It is generally accepted that men and women present with psychosis in different ways;
however, there is still a considerable knowledge gap about how the illness presents in the
early stages with regards to sex/gender differences. Based on findings from this study and
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from prior literature, it is presumed that women with psychotic disorders present with more
subtle symptoms than men, due to less severe negative symptoms and higher functioning.
This may cause the illness to be harder to detect, especially in the early course. Clinicians
may be able to tailor interventions specifically toward young men or women experiencing
early psychosis by better recognizing how symptoms differ between the sexes. Early
detection and intervention is of utmost importance in psychotic disorders,45 and
understanding sex and gender differences in clinical presentation can help advance the aim
of early detection.45

3.5.2

Limitations

The evidence from this review should be interpreted with consideration of several
limitations of the included studies, and of the review itself. Many of the studies included
in the review had small sample sizes, with more men than women. Although this is
representative of the distribution of FEP in clinical populations,24 this may limit the ability
to generalize the study results to all people experiencing FEP or early psychosis, especially
to women who may be receiving care outside the context of specialized early intervention
services.24 Definitions of FEP or early psychosis varied among the included studies, which
may have impacted the clinical presentation noted in each study. Many of the studies
limited their sample to those of a certain age, duration from symptom onset, or to those that
spoke a certain language. These restrictions may also limit the external validity of the study
findings, as the results may not be applicable to all people with early psychosis.
Furthermore, given that women tend to have a later age at onset,34 any age restrictions
would function to underrepresent women with FEP. Another limitation of most of the
included studies is the omission of cognitive symptoms. Evidence suggests that men and
women with early psychosis may differ in cognitive functioning,34 which may be due to
the positive role that estrogen plays in cognition.32 However, these symptoms were not
commonly reported throughout the literature. Lastly, sex and gender differences within the
included studies were often conflated, with the role of gender in the incidence and
presentation of psychosis being ignored. A major gap in the literature remains on the grey
areas of gender, and how these impact the clinical presentation of early psychosis. Future
research should explore exposures that differ between genders, such as childhood trauma
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or abuse, head injury, spring birth, in-utero or birth complications, or pregnancy,93 and
areas of gender fluidity, including LGBTQ+ people, intersex individuals, or individuals
with hormone dysfunction. Further research on the topic should include data from these
individuals to create a more cohesive understanding of the relative contributions of sex and
gender on symptoms of psychosis.
There are also several limitations of the overall review that should be considered. Inclusion
and exclusion criteria differed significantly across the included studies. Criteria such as age
of the patient, amount of time from symptom onset, inclusion of drug-induced psychosis,
and criteria used to define FEP or early psychosis varied between studies, which limits our
ability to draw conclusions about subgroups of early psychosis patients and increases the
heterogeneity in our data. The exclusion of UHR, CHR, or prodromal patients may
decrease generalizability of the findings, however; sex differences in symptoms for these
populations are out of the scope of this review. Additionally, although validated scales
were used in all included studies to obtain measures of symptomology, these scales differed
between studies and may have introduced heterogeneity in our pooled estimates, although
the findings were largely consistent across measurement tools in our subgroup analyses.
Finally, we were unable to differentiate between sex and gender in the present review. It is
still unknown whether differences in psychotic symptoms are due to biologic sex
differences or if gender may also play a role.

3.5.3

Conclusions

Our findings suggest that men with FEP or early psychosis experience more negative
symptoms and substance use than women, whereas women experience more depressive
symptoms and have higher functioning than men. Gender differences were not found for
positive symptoms or general psychopathology. The evidence from this study may help to
inform clinicians and researchers on better identifying FEP and early psychosis to facilitate
early intervention. Further population-based studies are needed to provide more substantial
evidence on sex/gender differences in clinical presentation of early psychosis, and
additionally, how these symptoms present outside the context of specialized early
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intervention services. Further research on the role of biological sex and gender factors in
the clinical presentation of psychotic disorders is warranted.
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Chapter 4

4

Sex Differences in the Clinical Presentation of Early
Psychosis in a Primary Care Setting

4.1 Abstract
Background: Primary care plays an important role in the help-seeking pathway for young
people experiencing early psychosis, but sex differences in clinical presentation in these
settings is unexplored. We used electronic medical records to explore sex differences in
clinical presentation to primary care in the one-year period prior to a first diagnosis of
psychotic disorder. Methods: We identified first-onset cases of non-affective psychotic
disorder over a 10-year period (2005-2015) using health administrative data (n=465).
This cohort was linked with electronic medical records (EMR) from primary care, where
detailed information on encounters in the year prior to first diagnosis was abstracted,
including a checklist of recorded psychiatric symptoms and other relevant behaviours,
and whether the first diagnosis was made by the family physician (FP). We used
modified Poisson regression models to examine the effect of sex on signs, symptoms, and
diagnoses, adjusted for various clinical and sociodemographic factors. Results: In the
period one year prior to first diagnosis of psychotic disorder, positive symptoms
(PR=0.76, 95%CI:0.58,0.98) and substance use (PR=0.54, 95%CI:0.40,0.72) were less
prevalent in the medical records of women. No other sex differences in symptoms were
found. Visits by women were more likely to be assigned a diagnosis of depression or
anxiety (PR=1.18, 95%CI:1.00,1.38), personality disorder (PR=5.49, 95%CI:1.22,24.62),
psychological distress (PR=11.29, 95%CI:1.23,103.91), and other mental or behavioural
disorders (PR=3.49, 95%CI:1.14,10.66), and less likely to be assigned a diagnosis of
substance use (PR=0.33, 95%CI:0.13,0.87) in the year prior to first diagnosis.
Conclusions: We identified some evidence of sex differences in the clinical presentation
of early psychosis and recorded diagnoses in the primary care EMR. Further research is
needed to better understand sex differences in clinical presentation in the primary care
context.
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4.2 Introduction
Psychotic disorders are a class of severe mental illnesses that typically have an onset in
adolescence or young adulthood and can cause a significant burden on those experiencing
them, their carers, and the healthcare system.8 The clinical presentation of these disorders
can be quite variable in terms of the age of onset, symptomatology, and course of illness,8,32
and the sex or gender of the person experiencing psychosis may explain some of this
variability.34 For example, the age of onset for psychotic disorders occurs later in life for
women than men, possibly owing to protective effects of hormones or difficulty identifying
the illness in women, resulting in a later age at diagnosis.34 The incidence of psychotic
disorder also tends to be slightly higher in men than women,32 which may be explained by
narrow diagnostic criteria or age restrictions, or women being less likely to be recognized
as having a psychotic disorder than men.32 Although women may not be diagnosed as
frequently as men, evidence suggests that women are more likely than men to voluntarily
seek help for mental health reasons.25,99 Finally, prior research suggests that women with
psychotic disorders may receive sub-optimal care due to an insufficient understanding of
how women are differently affected by these illnesses.37
These sex and gender differences in psychotic disorder likely arise from a complex
interaction of both biological and psychosocial factors,32 which may also have an impact
on clinical presentation. Individual studies on sex differences in symptoms have varying
results, but evidence from reviews indicate that men experience more severe negative
symptoms (i.e., social withdrawal, anhedonia, blunted affect) and have higher levels of
substance use than women, whereas women experience more severe affective symptoms
(i.e. depression, anxiety, mania) but have higher levels of functioning.34,100 Findings on sex
differences in the symptoms of psychosis are abundant; however, these differences have
yet to be studied outside of the context of specialized psychiatric services.
The identification of psychotic symptoms early in the course of illness is imperative for
improving clinical and functional outcomes, and can reduce suffering for the patients and
families involved.18 Timely access to treatment can be facilitated by family physicians
(FP), who are often the first point of contact for young people experiencing early
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psychosis.101 The pathways to care for early psychosis can be complex, involving multiple
contacts and services, including emergency departments.18 FPs and other primary care
practitioners play a key role in this pathway to care, with about one third of young people
with early psychosis in Ontario (Canada) receiving their first diagnosis of a psychotic
disorder in primary care.18 An additional third of early psychosis patients who received
their diagnosis in secondary or tertiary care had mental health contacts with a FP in the 6month period prior to first diagnosis.18 People experiencing early psychosis have been
found to make twice as many contacts with primary care practitioners in the period 6 years
leading up to a first diagnosis, compared to the general population.26 This includes visits
for all reasons, including mental, physical, and preventative health.26 Furthermore, those
that initiate their own help-seeking are more likely to seek help in a primary care setting
than in psychiatric or emergency services.18 Differences exist between men and women
with regards to help-seeking in primary care for early psychosis.25 Prior research indicates
that women seek help almost twice as often,25 and are more likely than men to contact
primary care practitioners for all reasons, including mental, physical, and preventative
health.26
Given the vital role that primary care physicians play in the pathway to care for people
with early psychosis, understanding clinical presentation in a primary care context is
important. Young people presenting to primary care are likely at an earlier stage of illness
than those presenting to secondary or tertiary care services, thus having a less acute
presentation and more insidious symptoms.18 The knowledge base on sex differences in
symptoms of early psychosis is limited to specialized settings, such as Early Psychosis
Intervention (EPI) services or other psychiatric settings, with a gap in the literature on how
young men and women experiencing early psychosis may present to primary care. To more
effectively detect and intervene for people with early psychosis who seek help in primary
care, we need a thorough understanding of the sex differences in symptoms that present in
these settings.
The overall objective of this study was to use electronic medical records, linked to
population-based health administrative data in Ontario, to explore sex differences in the
clinical presentation of early psychosis at presentation to primary care in the one-year
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period leading up to the first diagnosis of psychotic disorder. Specifically, we aimed to 1)
identify and describe sex differences in clinical presentation (i.e., signs and symptoms) of
early psychosis; 2) identify and describe sex differences in diagnoses made by the FP; and
3) adjust for the effect of clinical and sociodemographic factors on these sex differences.
In this paper, we use the term “early psychosis” to describe patients experiencing FEP, as
well as those in the prodromal phase of illness.

4.3 Methods
This study follows the REporting of studies Conducted using Observational Routinelycollected health Data (RECORD) guidelines for observational studies (Appendix 4A).102

4.3.1

Study Design and Case Definition

We obtained access to the administrative data holdings at ICES (formerly known as the
Institute for Clinical Evaluative Sciences), which is a not-for-profit research institute that
works with health-related data for the province of Ontario.103 Health administrative data is
generated by health care providers every time a service is delivered to a person in Ontario,
which may be used for billing, registration, transactions, record-keeping, and also to study
and evaluate health care delivery, use, and costs.104 Analysts at ICES used unique
identifiers to link patients between datasets.
We used the following health administrative databases to identify people with first onset
psychotic disorders:
•

The Registered Persons Database (RPDB) contains socio-demographic information on
all people covered by the Ontario Health Insurance Program (OHIP),105 including age,
sex, and neighbourhood income quintile. OHIP covers all medically necessary services
for nearly the entire population of Ontario, such as appointments with FPs, visits to
walk-in clinics and the emergency department, and medical tests and surgeries.106

•

The OHIP database contains information from physician billings, including the type of
service provided and the diagnosis assigned to each visit.107 It is estimated that 95% of
Canadian physicians submit billing claims.
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•

The National Ambulatory Care Reporting System (NACRS) database includes
ambulatory care data for both hospital-based and community-based care, including day
surgeries, outpatient clinics, and emergency departments.108

•

The Ontario Mental Health Reporting System (OMHRS) database includes information
on people admitted to designated adult psychiatric inpatient beds in Ontario.109

•

The Discharge Abstract Database (DAD) contains data on all discharges from inpatient
facilities, including deaths, sign-outs, and transfers.110 Any inpatient psychiatric
admissions not captured by the OMHRS database is included in DAD.

Using these databases, we identified first-onset cases of non-affective psychotic disorder
(i.e., schizophrenia, schizoaffective disorder, schizophreniform disorder, psychosis not
otherwise specified [NOS]) among people aged 14 to 35 years over a ten-year period (2005
to 2015), based on the presence of at least one of the following:
1. A primary discharge diagnosis of a non-affective psychotic disorder from a general
hospital bed [International Classification of Diseases (ICD), 9th Revision code
295.X, 297.X, 298.X; ICD-10 code F20 or F25]; or
2. A discharge diagnosis of non-affective psychotic disorder from a psychiatric
hospital bed [Diagnostic and Statistical Manual of Mental Disorders, 4th Edition
(DSM-IV, Axis I) code 295.X, 297.X, 298.X]; or
3. Two or more outpatient OHIP billing claims or emergency department visits within
a 12-month period with a diagnostic code for non-affective psychotic disorder
(ICD-9 code 295.X, 297.X, 298.X; ICD-10 code F20 or F25).
Prevalent cases were removed if there was evidence of contact with mental health services
for non-affective psychosis prior to the case accrual window (lookback of 25 to 35 years
based on year of diagnosis). People with a prior diagnosis of affective psychosis were not
excluded, and instead included as an incident case of non-affective psychosis from the date
of diagnosis change. This algorithm has been previously used by Anderson et al. to estimate
the incidence of first-onset psychotic disorders in Ontario.111 A modified version of the
algorithm has been validated against medical records and found to have a sensitivity of
91.6%, a specificity of 61.3%, a positive predictive value (PPV) of 67.4%, and a negative
predictive value (NPV) of 89.3% for chronic psychotic disorders.112
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4.3.2

Symptom and Behaviour Variables

Cases of first-onset non-affective psychotic disorder identified in the health administrative
data were then linked with the primary care EMR database at ICES to identify cases who
had records in the EMR in the one-year period prior to the first diagnosis of psychotic
disorder. The Electronic Medical Records Primary Care (EMRPC) database includes
detailed free-text information from visits to primary care, as well as other sources such as
consultation notes from specialists.113 The EMRPC database includes approximately 360
FPs practicing under a primary care reform model across Ontario, with similar gender and
urban/rural distributions compared to the broader population of Ontario FPs. Almost all
FPs in the EMRPC database are in group practice, and all FPs practice in a rostering model.
Over 300,000 patients and 400,000 physician-patient encounters are included in the
database over a one-year period. This represents approximately 2% of FPs in Ontario and
approximately 2% of the total Ontario population. This database was used to abstract more
detailed clinical information on encounters with primary care prior to first diagnosis of
psychotic disorder than would typically be available in the health administrative data,
including information on patient characteristics, psychotic disorder diagnosis, social
support, and signs/symptoms of psychosis.
We abstracted data on the symptoms and behaviours that early psychosis patients presented
with during primary care encounters in the one-year period leading up to the first diagnosis.
Prior studies114,115 and input from clinicians on the team (LP, AGM, AV, SHJ) were used
to develop the list of symptoms and behaviours to abstract. The data were abstracted from
the EMR using an abstraction platform at ICES, and a standardized abstraction manual was
created to guide this process for the abstractor. After linkage with the administrative data
cohort, 719 charts were identified in the EMRPC database. A FP (NS) abstracted data from
all charts using the abstraction platform and manual. A 5% selection of patient records
were abstracted twice to ensure quality control and assess intra-rater reliability, and
agreement ranged from 75% to 100%. To assess inter-rater reliability, the signs and
symptoms abstracted from the charts were validated by a second abstractor. Of the 719
charts, 381 patients had at least one symptom abstracted in the period 6-months prior to
index. We randomly selected 15% of this sample for validation, where a second abstractor
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independently abstracted data from these charts using the ICES platform and abstraction
manual, and agreement ranged from 92% to 100%.
Psychotic symptoms were abstracted from the EMR using items from the Early Detection
Primary Care Checklist (PCCL), consisting of 20 items. The PCCL is a validated tool used
to help identify first-episode psychosis in young people in primary care. Other signs,
symptoms, and vulnerabilities associated with psychosis that were not captured by the
PCCL were also abstracted, as well as any diagnosis or provisional diagnosis made by the
FP at each encounter. Signs and symptoms were flagged as yes or no based on whether the
primary care provider noted them in the medical record during the encounter. Symptoms
and behaviours were grouped to increase comparability with prior studies that explored
similar broad symptom groups,43,66,76,89 and to combine individual symptoms with low
frequencies.
1. Positive symptoms of psychosis, including delusions, hallucinations, and
disorganized thoughts or behaviour.
2. Negative symptoms of psychosis, including anhedonia, blunted affect, diminished
speech, social withdrawal, and avolition.
3. Mood symptoms, including depression and mania symptoms.
4. Anxiety symptoms, including anxiety, restlessness, and tension or nervousness.
5. Decreased functioning, including issues with personal hygiene, increased stress, or
deterioration in functioning.
6.

Cognitive symptoms, including poor memory and poor concentration.

7. ADHD symptoms, including hyperactive behaviour and impulsivity.
8. Substance use, including cigarette smoking, alcohol use, cannabis use, and use of
other street drugs.
9. Self-harm/suicidal behaviours.
10. Other symptoms and behaviours, including poor appetite, sleep difficulties,
aggression, lack of insight into mental health, psychosomatic complaints, and
psychosocial stressors.
We also abstracted information on the diagnosis assigned to the encounter by the FP and
whether the diagnosis was provisional.
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4.3.3

Other Variables

The main exposure of interest was the sex of each patient, which was obtained from the
health administrative data. Sex was used as a binary variable (Male, Female).
We obtained information on other patient characteristics that may be differentially
associated with clinical presentation of early psychosis among men and women. These
included age at first diagnosis, neighbourhood-level income quintile, and rurality of
residence. Age at first diagnosis was used as an ordinal variable (15-20 years, 21-25 years,
26-30 years, 31-35 years), and was included because among people with psychotic
disorders, the age of onset or age of diagnosis often differs among men and women.34
Furthermore, the age of the person experiencing early psychosis may have an impact on
the clinical presentation of the illness.116 Neighbourhood-level income quintile was an
ordinal variable, ranging from lowest to highest income quintile, and was included because
prior research indicates that those with lower incomes may experience more psychotic
symptoms,117,118 and incomes differ between men and women with psychotic disorders.119
Rurality of residence was used as a binary variable (Rural, Non-Rural), which was included
because evidence also suggests that living in urban areas may increase psychotic symptoms
and risk of developing a psychotic disorder,15 and this risk may be stronger for men than
women.120 We obtained other patient information for the purpose of describing the sample.
These variables include index diagnosis (Schizophrenia Spectrum Disorder, Psychosis
NOS), family history of bipolar or psychosis, and if the family is concerned/expressed
worry about the patient.
Service-related variables included the number of help-seeking visits prior to the index date,
whether or not the patient was rostered to the FP, time on EMR, and number of John
Hopkins ADGs (Aggregated Diagnosis Groups), Number of help-seeking visits was used
as a count variable, rostering to the FP was a binary variable (True, False), and time on
EMR is the number of days the patient has been on the EMR, which was used as a
continuous variable. These were included in the analysis because evidence suggests that
primary care service use differs between men and women with early psychosis,25,26 which
may encompass number of help-seeking visits, whether a patient is rostered to a FP, and
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the amount of time spent on the EMR. Furthermore, it is well-established that timely access
to treatment and contact with a FP can improve clinical presentation and long-term
outcomes.18 John Hopkins ADGs are diagnostic clusters derived from the health
administrative data, ranging from zero to 32.121 ADGs are used to identify and score
comorbidities, and are based on five clinical criteria of the condition, including the
duration, severity, diagnostic certainty, etiology, and specialty care involvement.122
Number of ADGs was used as a categorical variable (Low (<5), Medium (6-9), High (10
or more)), and was included because comorbidities are common among people with
psychotic disorders,123 and prior research suggests there are sex differences in patterns of
multimorbidity.124

4.3.4

Data Analysis

All analyses were conducted using SAS Enterprise Guide 7.1.125 People missing data on
age and sex were excluded (<1%). We calculated descriptive statistics for
sociodemographic, clinical, and service use characteristics. Descriptive characteristics of
the sample were summarized using frequencies and percentages for categorical data and
means with standard deviations (SD) for continuous data. Our descriptive analyses were
stratified according to sex. We also computed variance inflation factors (VIF) and tolerance
to investigate multicollinearity for the following: age category, time on EMR, total ADGs,
and number of help-seeking visits. If values of VIF were below 10, and values of tolerance
above 0.1, it can be assumed that multicollinearity is not a threat in the analysis.126
First, we limited the sample to those who had a record in the EMR and data on clinical
presentation in the one-year period leading up to a first diagnosis of psychotic disorder.
Second, we estimated the proportion of men and women who experienced each sign and
symptom of early psychosis in the one-year period leading up to a first diagnosis. Next, we
compared these proportions using modified Poisson regression models with robust
variance estimators for each symptom using the proc genmod command in SAS Enterprise
Guide 7.1. Modified Poisson regression models are suitable for the analysis of binomial
data, and robust variance estimators prevent the error from being overestimated.127
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We then further limited the sample to those who had a diagnosis made by the FP in the
EMR in the period one year leading up to a first diagnosis. We estimated the proportion of
men and women with each diagnosis over this period, and whether the diagnosis was
provisional. These proportions were then compared using modified Poisson regression
models with robust variance estimators using the proc genmod command.
Next, we fit adjusted modified Poisson regression models to adjust for the effect of clinical
and sociodemographic factors (i.e., age at index, neighbourhood income quintile, rurality,
number of help-seeking visits, rostered to FP, time on EMR, number of ADGs) on the sex
differences in clinical presentation or diagnoses made by the FP. This was done to
determine whether these factors had an effect on the relationship between sex and clinical
presentation of early psychosis.
The results of the unadjusted and fully adjusted analyses were similar; therefore, we present
fully adjusted prevalence ratios (PRs) with associated 95% confidence intervals (CI). PRs
were reported instead of odds ratios (ORs) because the outcomes of interest are not rare,
and ORs would be overestimated. Associations were considered statistically significant
when the 95% confidence intervals did not include one.

4.4

Results

The initial sample consisted of 572 people (255 women, 317 men) identified with a first
onset of non-affective psychotic disorder in the health administrative data who also had an
electronic medical record in the EMRPC database. People who did not have a visit with a
FP for the one-year period prior to the first diagnosis of a psychotic disorder and were
therefore missing symptom data were removed from the sample (n=107). People who did
not have a diagnosis assigned by the FP recorded in the EMR were not removed from the
sample but were not included in the analyses on sex and diagnosis (n=163). The final
sample consisted of 465 people, of whom 215 were women (46.2%) and 250 were men
(53.8%).
The characteristics of the analytic sample are summarized in Table 4.1. Women had a mean
age at diagnosis of 24.5 years, and men had a mean age at diagnosis of 23.4 years. Women
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had an average of 1036 days (SD=1042.1) on the EMR and had an average of 9 (SD=9.1)
help-seeking visits in the year leading up to first diagnosis, whereas men had an average
of 979 days (SD=1049.7) on the EMR had had an average of 5 (SD=5.0) help-seeking visits
in the year leading up to first diagnosis. Seventy percent of women and 72% of men were
rostered to a FP. About 14% of both women and men’s families expressed worry or concern
for their well-being. No threat of multicollinearity was indicated through the analysis of
tolerance or VIF.

49

Table 4.1: Sample characteristics of early psychosis patients (n=465)
Variable
Age at index
Time on EMR (days)
Number of help-seeking visits
Age category
15-20 years
21-25 years
26-30 years
31-35 years
Neighbourhood income
quintile
1 (lowest)
2
3
4
5 (highest)
Rurality
Rural
Non-Rural
Total ADG category
Low (<5)
Medium (6-9)
High (10 or more)
Rostered to family physician
The family is concerned/has
expressed worry about the
patient
Index diagnosis
Schizophrenia Spectrum
Disorder
Psychosis NOS
Family History of Bipolar or
Psychosis

Women (n=215)
Mean
SD
24.46
5.97
1036.48
1042.09
8.88
9.13
N
%

Men (n=250)
Mean
23.36
979.45
5.35
N

SD
5.42
1049.66
4.98
%

70
51
49
45

32.6
23.7
22.8
20.9

94
66
55
35

37.6
26.4
22.0
14.0

50
50
46
36
33

23.3
23.3
21.4
16.7
15.3

59
49
47
43
52

23.6
19.6
18.8
17.2
20.8

32
183

14.9
85.1

37
213

14.8
85.2

75
79
61
151
29

34.9
36.7
28.4
70.2
13.5

147
72
31
181
36

58.8
28.8
12.4
72.4
14.4

88

40.9

111

44.4

127
<6

59.1
<2.8

139
8

55.6
3.2

Note: ADG = Aggregated Diagnosis Group, Psychosis NOS= Psychosis Not Otherwise Specified.
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The results from the analysis of sex differences in the signs and symptoms of psychosis are
presented in Table 4.2. In early psychosis presentations to primary care, the most
commonly recorded symptoms were positive symptoms (33.5% of women, 38.0% of men),
mood symptoms (54.4% of women, 47.6% of men), anxiety symptoms (61.9% of women,
56.4% of men), decreased functioning (36.7% of women, 34 4% of men), substance use
(25.1% of women, 37.6% of men), and sleep difficulties (37.2% of women, 31.2% of men).
In the fully adjusted analyses, we found that positive symptoms were less prevalent in
women compared to men (PR=0.76, 95%CI=0.58,0.98), specifically delusions (PR=0.57,
95%CI=0.40,0.82). Women had a lower prevalence of overall substance use (PR=0.54.
95%CI=0.40,0.72) relative to men, specifically alcohol use (PR=0.45, 95%CI:0.24,0.85)
and cannabis use (PR=0.38, 95%CI:0.24,0.60). There were no significant differences
between women and men in the prevalence of negative symptoms, mood symptoms,
anxiety symptoms, functioning, cognitive symptoms, ADHD symptoms, self-harm or
suicidal behaviours, or other symptoms and behaviours.
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Table 4.2: Unadjusted and adjusted analysis of sex on clinical presentation of early
psychosis
Symptom

Women
(n=215)
N
%
72
33.5

Men
(n=250)
N
%
95
38.0

PR
0.88

95%CI
0.69, 1.13

PR
0.76

95%CI
0.58, 0.98*

Delusions

42

19.5

73

29.2

0.67

0.48, 0.93*

0.57

0.40, 0.82*

Hallucination
Disorganized
Thoughts/ Behaviours

35
30

16.3
14.0

36
38

14.4
15.2

1.13
0.92

0.74, 1.73
0.59, 1.43

1.02
0.79

0.65, 1.61
0.50, 1.26

Negative Symptoms
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23.3

56

22.4

1.04

0.74, 1.45

0.90

0.63, 1.27

Mood Symptoms

117

54.4

119

47.6

1.14

0.96, 1.37

0.98

0.82, 1.18

Depressive Mood

111

51.6

110

44.0

1.17

0.97, 1.42

1.01

0.83, 1.23

Mania Symptoms

52

24.2

43

17.2

1.41

0.98, 2.02

1.10

0.76, 1.60

Anxiety Symptoms

133

61.9

141

56.4

1.10

0.94, 1.28

0.94

0.81, 1.10

Decreased
Functioning
Cognitive Symptoms

79

36.7

86

34.4

1.07

0.84, 1.36

0.88

0.68, 1.13

38

17.7

42

16.8

1.05

0.71, 1.57

0.92

0.60, 1.42

ADHD Symptoms

30

14.0

22

8.8

1.59

0.94, 2.66

1.11

0.65, 1.88

Substance Use

54

25.1

94

37.6

0.67

0.50, 0.88*

0.54

0.40, 0.72*

Smoking
Alcohol
Cannabis

36
15
24

16.7
7.0
11.2

38
34
66

15.2
13.6
26.4

1.10
0.51
0.42

0.73, 1.67
0.29, 0.92*
0.28, 0.65*

0.86
0.45
0.38

0.55, 1.35
0.24, 0.85*
0.24, 0.60*

Other Street Drugs

14

6.5

21

8.4

0.78

0.40, 1.49

0.53

0.26, 1.08

Self-Harm/ Suicidal
Behaviours

67

31.2

58

23.2

1.34

0.99, 1.81

1.11

0.80, 1.52

Poor Appetite
Sleep Difficulties

38
80

17.7
37.2

28
78

11.2
31.2

1.58
1.19

1.00, 2.48*
0.93, 1.54

1.39
1.02

0.86, 2.24
0.78, 1.34

Aggression
Lack of Insight

59
<6

27.4
<2.8

69
7

27.6
2.8

0.99
0.17

0.74, 1.34
0.02, 1.34

0.77
N/A

0.56, 1.05

Psychosomatic
Complaints
Psychosocial
Stressors

<6

<2.8

<6

<2.4

1.74

0.29, 10.34

0.91

0.74, 1.12

102

47.4

112

44.8

1.06

0.87, 1.29

N/A

Positive Symptoms

Unadjusted

Adjusted

Other Symptoms/
Behaviours

Note: All estimates are women compared to men. N/A analyses were unable to be computed due to low sample sizes.
*p < .05
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The results from the analysis on sex differences in the diagnoses made by the FP can be
found in Table 4.3. This sample consisted of 302 people, 144 women (47.7%) and 158 men
(52.3%). The diagnoses that were most commonly recorded during visits to primary care
included depression or anxiety (71% of women, 60.8% of men), psychotic disorder (32.6%
of women, 27.2% of men), or psychosis symptoms (22.2% of women, 29.1% of men). In
the fully adjusted analysis, we found that a diagnosis of substance/alcohol use/addiction
was less prevalent in women compared to men (PR=0.33, 95%CI=0.13,0.87). Additionally,
a diagnosis of psychological distress was more prevalent in women than men (PR=11.29,
95%CI=1.23,103.91). We were unable to run fully adjusted models for personality disorder
and other mental health diagnoses due to small numbers, however these were both
significantly more prevalent among women (PR=5.49, 95%CI=1.22, 24.62 and PR=3.49,
95%CI=1.14, 10.66, respectively). No differences were found between men and women
for a diagnosis of psychotic disorder, psychosis symptoms, self-harm/suicidality, other
nonspecific prodromal symptoms, neurological or neurodevelopmental condition. There
was also no difference between men and women in whether the diagnosis made by the FP
was provisional.
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Table 4.3: Unadjusted and adjusted analysis of sex on diagnoses made by the FP
prior to psychotic disorder diagnosis
Diagnosis

Women
(n=144)
N
%
103
71.5

Men
(n=158)
N
%
96
60.8

PR
1.18

95% CI
1.00, 1.38*

PR
1.10

95% CI
0.93, 1.30

Substance/ alcohol
use/addiction

<6

<4.2

11

7.0

0.50

0.18, 1.40

0.33

0.13, 0.87*

Personality disorder

10

6.9

<6

<3.8

5.49

1.22, 24.62*

N/A

Psychological
distress
Psychotic disorder

12

8.3

<6

<3.8

13.17

1.73, 100.00*

11.29

1.23, 103.91*

47

32.6

43

27.2

1.20

0.85, 1.70

1.11

0.77, 1.60

Psychosis symptoms

32

22.2

46

29.1

0.76

0.52, 1.13

0.83

0.56, 1.24

Self-harm/
suicidality
Other nonspecific
prodromal
symptoms

7

4.9

<6

<3.8

2.56

0.67, 9.71

N/A

<6

<4.2

<6

<3.8

1.46

0.33, 6.43

N/A

Other Mental or
Behavioural
Disorders

12

8.3

<6

<3.8

3.49

1.14, 10.66*

N/A

Neurological or
Neurodevelopmental
Condition

21

14.6

24

15.2

1.02

0.58, 1.78

0.95

0.54, 1.67

FP was sure of
psychotic disorder
diagnosis

38

26.4

33

20.9

1.05

0.85, 1.31

1.06

0.86, 1.30

Depression/ anxiety

Unadjusted

Adjusted

Note: Frequency missing = 163. All estimates are women compared to men. N/A analyses were unable to be computed due to small
sample sizes.
*p < .05
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4.5

Discussion

Our findings suggest that women with early psychosis are less likely to present to primary
care with positive symptoms than men, particularly delusions. Some prior studies from
specialized psychiatric services are consistent with these findings;43,76,89 however, many
studies have found no differences between men and women on positive symptoms.66,80,128
Men tend to have a less insidious clinical presentation at first onset than women,37 and
women are more likely to seek help in primary care than men.26 This could indicate that
women without positive symptoms are overrepresented in primary care, and women with
positive symptoms may be going straight to secondary or tertiary care. This could account
for the sex differences found in presentation to primary care, but not later in the course of
illness in secondary or tertiary care. It was also found that men present to primary care with
more substance use than women, particularly alcohol and cannabis use. These findings
align with evidence from prior studies in specialized care.32,34,66,88 A higher prevalence of
alcohol and substance use among men is also evident in the general population,129 so it is
unsurprising that these tendencies carry over to people with early psychosis. Additionally,
evidence from previous studies suggests that substance use, specifically the use of
cannabis, can act as a risk factor for developing psychotic symptoms and disorders.130 This
may help explain why substance use is common in the clinical presentation of young people
in primary care.
There were no sex differences found for other signs and symptoms of early psychosis,
including negative symptoms, mood symptoms, anxiety, and functioning. This contradicts
findings in reviews from Ochoa at al. and Riechler-Rössler et al., where it was found that
men experience more negative symptoms than women, and women experience more mood
symptoms and anxiety, and have higher levels of functioning than men.32,34 The trends we
observed may be due to physicians’ difficulty in recognizing symptoms and recording them
in the EMR due to variability in clinical presentation over time.131 Evidence suggests that
FP’s are more comfortable identifying overt symptoms of psychosis such as hallucinations,
delusions, and bizarre behaviour, but struggle to identify less obvious psychotic symptoms
such as functional decline.27 Furthermore, patients with these insidious symptoms are more
likely to present to primary care.27 Negative symptoms may be less likely to be identified
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by the FP, which may explain why differences in these symptoms were not found. The
ability of FPs to recognize psychotic symptoms may also differ by sex – it has been
suggested that physicians have greater difficulty detecting the presence of a psychotic
disorder in women relative to men,34,37 which would be heightened in the context of early
psychosis presentations in a primary care context. It has been estimated that FPs only come
into contact with one or two patients per year with early psychosis, which would explain a
low comfort level in identifying symptoms of psychosis.26 It is also possible that FPs
recognize certain early psychosis symptoms, but attribute them to something other than
psychosis. For instance, although depression and anxiety are often observed throughout the
course psychotic disorders,132 negative symptoms of psychosis, such as social withdrawal,
may be mistaken as a depressive symptom.
We found that a diagnosis of depression or anxiety, personality disorder, psychological
distress, or other mental or behavioural disorders (i.e., behaviour disorders, PTSD, eating
disorders, sleep disorders) were more common among women, whereas a diagnosis of
substance use, alcohol use, or addiction was more common among men. This is consistent
with prior literature on gender differences in mental disorder diagnoses, which suggests
that women are more likely to be diagnosed with internalizing disorders, such as mood and
anxiety disorders, and men are more likely to be diagnosed with externalizing disorders
such as substance use disorders.129 There are many possible explanations for this observed
sex difference, including biologic factors, psychosocial factors, and a combination of
these.129 Given the wide range of signs and symptoms of early psychosis, the diagnostic
process is often complex.26 It is possible that patients were in the prodromal phase of a
psychotic disorder at the time that a FP gave these diagnoses, and full criteria for a
psychotic disorder may not have been met. This would explain the high frequencies of
other diagnoses such as depression or anxiety, and a high likelihood that the physician was
unsure of the diagnosis. Additionally, FPs may be hesitant to assign a psychotic disorder
diagnosis due to the consequences this may hold for the patient.133
Our findings suggest that women make more help seeking visits to primary care than men
in the one-year period preceding a first diagnosis of psychotic disorder. This trend is
consistent with prior research, where women with psychotic disorders were found to make
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almost twice as many help-seeking contacts for mental health reasons as men.25
Additionally, young women were more likely than young men to initiate mental health
help-seeking contacts on their own,25 whereas young men often relied on friends or family
to make the first help-seeking contact.51 This could indicate that women have more
opportunities to report their symptoms, but also that women may not receive referrals from
family physicians as quickly as men. People with early psychosis who first present to
primary care are likely different from those first presenting to secondary or tertiary care
services,18 making it difficult to directly compare our findings to studies conducted in other
settings. Furthermore, the patients that make up our sample may be in the prodromal phase
of illness and have not yet had psychosis onset. This could mean that our sample is not
comparable to samples from secondary or tertiary care. These patients are likely in an
earlier stage of illness than those presenting to specialized services, which may mean a less
acute clinical presentation and more insidious symptom profile.
Our study is the largest Canadian study to date to explore sex differences in symptoms of
psychosis, and the first to explore psychotic disorder symptomology with a focus on
presentation in a primary care context. Further research on this topic could incorporate
information from electronic medical records, patient self-reports, and standardized
symptom measurement tools such as the Positive and Negative Syndrome Scale.134 This
would allow better quantification of sex differences in symptoms, including both
prevalence and symptom severity. Future studies should also examine early psychosis
symptoms at multiple time points to explore the stability in sex differences over time.

4.5.1

Limitations

This study has some important limitations to consider. The use of pre-existing databases
and retrospectively constructed cohorts limits our analyses to variables that are available
in the data holdings. The variables available from ICES do not include symptom severity,
which allows us to comment only on sex differences in the presence of symptoms.
Additionally, there may be differences across physicians in charting practices with respect
to the level of detail on symptoms that are recorded in the EMR. We were unable to account
for physician characteristics that may contribute to these differences. Charting practices
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among FPs may also differ across male and female patients, with prior research on the
general population indicating that women may give a more complete history, but also may
receive less care than men.37,135 Due to the lack of a standardized screening tool used among
FPs, we are unable to identify whether symptoms of psychosis were not present, or if the
FP failed to record them in the EMR. The data holdings also do not include important
confounding factors such as culture or ethnicity,136 which may play a role in differential
clinical presentation by sex. We are unable to identify affective psychotic disorders within
the health administrative data, limiting our cohort to non-affective psychoses only. A fourdigit diagnostic code is used to identify affective psychotic disorders; however, three-digit
diagnostic codes are used in the OHIP database, which limits our ability to identify these
disorders in outpatient settings. Therefore, we are unable to generalize our findings to all
cases of early psychosis. Further, diagnostic codes may not be a reliable source for
identifying cases of psychosis, as they may not provide an accurate description of the
reason for contact with mental health services. All contacts with primary care in Ontario
were not represented in the data holdings, as only a small proportion of Ontario FPs and
patients are represented in the EMRPC database. Our analysis on sex differences in
diagnoses assigned by the FP was further limited by missing data. Additionally, we were
unable to see the diagnostic codes FPs submitted for OHIP billing, which may differ from
the diagnoses recorded by the FP in the EMR. Lastly, we were unable to account for the
role that gender identity may play in psychotic symptom differences.32

4.5.2

Conclusions

Our study identifies some sex differences in the clinical profile of early psychosis
presenting to primary care for mental health services. Our findings indicate that one year
preceding the first diagnosis of a psychotic disorder, men present with more positive
symptoms and substance use than women. No sex differences were noted for other
symptoms of early psychosis. We found that one year before the psychotic disorder
diagnosis, more women were diagnosed with depression or anxiety, personality disorders,
psychological distress, and other mental or behavioural disorders by the FP, whereas more
men were diagnosed with substance use, alcohol use, or addiction. Given the crucial role
that the FPs and primary care play in the pathway to care for early psychosis, there is a
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need to understand the differences in clinical presentation between men and women.
Findings from this study may be used to highlight the need for continued education for
primary care practitioners. This would facilitate better detection of first-episode psychosis
at the primary care level and allow for early intervention of psychotic disorders. In turn,
decreasing the duration of untreated psychosis could allow for improved clinical and
functional outcomes for young people with first-episode psychosis. Further research is
needed to better understand sex differences in symptoms of early psychosis outside the
context of specialized services.
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Chapter 5

5

Synthesis and Conclusion

This chapter aims to synthesize and contextualize the findings from Chapters 3 and 4 of
this thesis to the larger body of literature. Together, these studies build a greater
understanding of sex differences in the clinical presentation of psychosis in primary care.
The research contributions and limitations of our studies will be noted. Finally, we will
discuss clinical implications, and direction for future studies in this area.

5.1 Summary of Studies
Although sex differences in symptoms of psychosis have been well documented in
specialized services, findings are inconsistent across studies, and a gap remains on the
clinical presentation of young men and women with early psychosis in other settings. The
overall aim of thesis was to explore sex differences in clinical presentation of early
psychosis in the context of primary care using two independent analyses. First, we
conducted a systematic review and meta-analysis to synthesize existing literature on
sex/gender differences in symptoms of early psychosis (Chapter 3). This provided context
for our subsequent study, in which we used health administrative data linked with
electronic medical records (EMR) in Ontario, Canada to explore sex differences in clinical
presentation of early psychosis in a primary care setting (Chapter 4).
Our systematic review and meta-analysis included studies that examined sex or gender
differences in symptoms of early psychosis. All 35 included studies examined sex of
participants, with no studies measuring gender, and all studies drew their samples from
specialized settings. We found that men with early psychosis experienced more severe
negative symptoms (SMD=-0.15, 95%CI=-0.21, -0.09), whereas women experienced more
severe depressive symptoms (SMD=0.21, 95%CI=0.14,0.27) and had higher functioning
(SMD=0.16, 95%CI=0.10,0.23). We also found that women with early psychosis had a
lower prevalence of substance use issues than men (PR=0.65, 95%CI=0.61,0.69).
Our EMR analysis from primary care found that one year preceding the first diagnosis of
psychotic disorder, positive symptoms (PR=0.76, 95%CI:0.58,0.98) and substance use
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(PR=0.54, 95%CI:0.40,0.72) were less prevalent in the medical records of women. We did
not find any other sex differences in symptoms at presentation to primary care. We also
found that visits by women were more likely to be assigned a diagnosis of depression or
anxiety (PR=1.18, 95%CI:1.00,1.38), personality disorder (PR=5.49, 95%CI:1.22,24.62),
psychological distress (PR=11.29, 95%CI:1.23,103.91) and other mental or behavioural
disorders (PR=3.49, 95%CI:1.14,10.66), and less likely to be assigned a diagnosis of
substance use, alcohol use, or addiction (PR=0.33, 95%CI:0.13,0.87).

5.2 Synthesis
In this section, we will compare findings from our two studies and discuss these findings
in the context of existing literature.
In our EMR analysis, we found that positive symptoms were less prevalent in the medical
records of women (PR=0.76, 95%CI:0.58,0.98). This is in contrast with our findings from
the systematic review and meta-analysis, in which we found no differences in positive
symptoms between men and women with early psychosis. Prior research indicates that
women are more likely to seek help in primary care than men,26 but also that men have a
more acute clinical presentation than women at first onset.37 Taken together, this may
account for the difference in findings between studies, as women without positive
symptoms may be overrepresented in primary care. Our two studies had similar findings
with regards to sex differences in substance use among people with early psychosis. We
found that substance use was less prevalent in the medical records of women than men
(PR=0.54, 95%CI:0.40,0.72) (Chapter 4), and similarly, that the risk of substance use was
lower in women than in men (RR=0.65, 95%CI=0.61,0.69) (Chapter 3). Although we did
not find any other sex differences in signs and symptoms of early psychosis in our EMR
analysis, our systematic review and meta-analysis found that men experienced more severe
negative symptoms (SMD=-0.15, 95%CI=-0.21, -0.09), whereas women experienced more
severe depressive symptoms (SMD=0.21, 95%CI=0.14,0.27) and had higher functioning
(SMD=0.16, 95%CI=0.10,0.23).
The small sample size and lack of standardization in charting practices across physicians
may help explain why findings from our EMR analysis differed from the systematic review
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and meta-analysis. Furthermore, although our systematic review and meta-analysis
captured sex differences in the severity of psychotic symptoms, the EMR analysis was
limited to comment only on the presence of symptoms as recorded in the medical records,
making it difficult to directly compare results from the separate studies. This may help
explain some of the differences found between our study and prior literature, as many other
studies examined symptom severity using validated instruments.66,80,128 Our EMR analysis
included only cases of non-affective psychosis, whereas our systematic review and metaanalysis included cases of both affective and non-affective psychosis. This may also help
explain contrasting findings, as people with affective and non-affective psychotic disorders
differ in a number of ways, including their gender and clinical presentation.137 Moreover,
the different clinical settings between the studies can account for differences in findings.
Evidence suggests that people with early psychosis who first present to primary care are
different than those presenting to secondary or tertiary care, and that people access primary
care earlier in the course of illness.18,25 People presenting to primary care may have more
subtle and insidious symptoms, which may be difficult for FPs to identify. 114 This could
indicate differences in clinical presentation to primary care compared to other services, and
account for differences in findings between the two studies. Results from this study cannot
be easily compared to prior research; however, our findings are highly novel and important
to the larger body of literature.

5.3 Research Contributions
The chapters of this thesis add to the body of literature on how young men and women with
early psychosis present differently to mental health services, specifically in the primary
care context. To our knowledge, we conducted the first systematic review and metaanalysis to quantify sex differences in symptoms of psychosis specifically in the early
course of illness (Chapter 3). This study clarified findings from the larger body of literature
and contributed to understanding how sex differences in the early course may differ from
sex differences later in the course of illness. Our study using EMR data is the first study to
explore sex differences in clinical presentation of early psychosis with a focus on primary
care, and the largest Canadian study to date to explore sex differences in symptoms of
psychosis (Chapter 4). Prior literature has focused on the presentation of early psychosis

62

in specialized settings, with our study filling the gap of presentation to a primary care
setting.

5.4 Limitations
Our systematic review and meta-analysis has some important limitations. Of the studies
included, small sample sizes and narrow inclusion criteria (such as age or duration from
symptom onset) were concerns for generalizability of findings. Furthermore, sex
differences in cognitive symptoms of psychosis were overlooked throughout the literature.
The overall review was also limited by heterogeneity of data, and the inability to
distinguish between sex and gender. The role of gender in the clinical presentation of early
psychosis is still underrepresented in the literature, and we were unable to determine
whether the differences we found in psychotic symptoms were due to biologic sex or
gender factors.
The primary limitation of our EMR analysis stems from the small sample size captured by
the EMRPC database. Only a small proportion of Ontario family physicians (FPs) and
people with early psychosis were captured in this study, impacting the representativeness
of our findings. The use of administrative data limits our ability to determine whether
symptoms of psychosis were not present, or if the FP did not record them in the EMR.
There may be differences between FPs in terms of their charting practices, which also may
differ between men and women patients.37,135 The use of a standardized screening tool for
identifying early psychosis in primary care would help to mitigate this limitation in future
studies. Due to the use of pre-existing databases and the variables that were available to us,
our study was limited to a focus on the presence of symptoms, rather than symptom
severity. This study was able to capture sex of the patients included, however, there was
no measurement of gender. This concept has often been ignored in mental health research,
and is also a limitation of the present study.31

5.5 Clinical Implications
Our study highlights the importance of recognizing sex differences in the clinical
presentation of early psychosis, namely in the context of primary care. Given that family
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physicians (FPs) and primary care are often the first point of contact for early psychosis
help-seeking,25,138 and early intervention can help improve clinical and functional
outcomes,2 recognizing psychotic symptoms at this stage is a clinical imperative. Our
findings suggest that men and women differ in their clinical presentation of early psychosis,
which has important implications for clinical practice. Although we found that positive
symptoms and substance use were less common in the medical records of women, we did
not find any other sex differences in clinical presentation, which could indicate that FPs
are not identifying or recording all early psychosis symptoms.
The findings from this thesis demonstrates the need for further education of the signs and
symptoms of early psychosis, and how they differ among men and women. Such
opportunities should be available for primary care providers in particular, allowing for
more timely recognition and intervention of psychotic disorders. Prior research has
indicated that FPs only come into contact with one to two early psychosis patients per year
and they lack knowledge on identifying more subtle symptoms of psychosis, such as
functional decline.27 We found that FPs were more likely to assign a diagnosis of
depression or anxiety, personality disorders, psychological distress and other mental or
behavioural disorders to women, whereas they were more likely to assign a diagnosis of
substance use, alcohol use, or addiction to men. This could further indicate a low comfort
level with early psychosis among FPs in Ontario. Prior research, as well as findings from
the present study, emphasize the need for continuing medical education of primary care
providers in recognizing and responding to early psychosis symptoms.

5.6 Future Studies
Future research is needed to better assess sex and gender differences in the clinical
presentation of early psychosis in the context of primary care. Integration of information
from medical records, patient self-reports, and a standardized symptom measurement tool
used across FPs would allow for the symptom profile of patients to be examined in much
greater detail, examining both symptom prevalence and severity. The use of both
administrative and patient-level data would provide more certainty about accuracy of data,
and increase comparability with prior studies in specialized settings.139 Furthermore, it
would be useful to explore the effect of clinical and sociodemographic factors on sex
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differences in clinical presentation. Although we adjusted for these factors in the present
study, it would be an interesting point of future studies to explore these factors further.
Studies with larger sample sizes, a wider age and criteria of inclusion, and records at
multiple time points are needed to better quantify sex differences in clinical presentation,
which may evolve over the course of illness. Larger studies that include patients of all ages
with both affective and non-affective psychotic disorders are needed to help generalize
findings to all patients experiencing early psychosis in Ontario, and to understand sex
differences between different populations of early psychosis patients. Longer term studies
would enable us to see the stability of clinical presentation over the course of illness, and
moreover, how sex plays a role in changes in clinical presentation over time.
Lastly, future studies should consider the role of both sex and gender in differences in
clinical presentation of early psychosis. There are many grey areas of these variables that
prior research, including the present study, have not accounted for. Future studies should
consider populations such as LGBTQ+ people, intersex people, or individuals with
hormone dysfunction to provide clarity on biological, social, and psychological factors that
impact clinical presentation of early psychosis. Furthermore, it would be useful to consider
exposures that differ between men and women that could contribute to differential clinical
presentation. Some of these factors could include childhood trauma or abuse, head injury,
spring birth, in-utero or birth complications, or pregnancy.12,98

5.7 Conclusions
The primary objective of this thesis was to identify and describe sex differences in the
clinical presentation of early psychosis in the context of primary care. Our systematic
review and meta-analysis found that among people with early psychosis, men with early
psychosis experienced more severe negative symptoms, whereas women experienced more
severe depressive symptoms and had higher functioning. We also found that women with
early psychosis had a lower prevalence of substance use issues than men. However, these
findings were limited to samples recruited from specialized psychiatric services. Our
subsequent analysis of medical records in primary care found that in the period one year
preceding the first diagnosis of psychotic disorder, positive symptoms and substance use
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were less prevalent in the medical records of women. No sex differences were noted for
other symptoms of early psychosis. We also found that one year before the psychotic
disorder diagnosis, more women were diagnosed with depression or anxiety, personality
disorders, psychological distress and other mental or behavioural disorders by a family
physician and were less likely to be assigned a diagnosis of substance use, alcohol use, or
addiction. Overall, this thesis contributes evidence on the sex differences in symptoms of
early psychosis, and further contextualizes these differences in a primary care setting. The
findings from this thesis highlight the importance of understanding how men and women
differently present with early psychosis outside of specialized services and serves to allow
for better detection of early psychosis at the primary care level.
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INTRODUCTION
Rationale
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Objectives
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METHODS
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Specify the inclusion and exclusion criteria for the review and how studies were grouped for the syntheses.

Information
sources
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Search strategy
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process
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Appendix 3B: Sex/gender differences in symptoms of psychosis – term harvesting
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Symptoms

Symptom*

sex OR gender
OR "sex
difference" OR
"gender
difference" OR
men OR women
OR male OR
female OR
"Gender
Identity" OR
"Sex Factors"
OR "Sex
Differentiation"
7,603
2,068

(MH "Sex
Factors") OR "sex
difference*" OR
"gender
difference*" OR
“sex” OR
“gender”

sex OR gender
OR "sex
difference" OR
"gender
difference"

sex OR gender OR
exp Human Sex
Differences OR
“sex difference” OR
“gender difference”

Sex, gender, difference

1,505
1,499

597
581

821
807

Total: 10,526
Total: 4,955

(MH "Signs and
Symptoms+")
OR
"symptom" OR
(MH
"Symptoms+")

TOTAL AFTER REMOVING DUPLICATES:

4,436
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Appendix 3C: Inclusion and exclusion criteria
PECOS
Component
Population

Inclusion Criteria

Exclusion Criteria

First episode or early psychosis patients –
must either have a diagnosis of
psychosis/psychotic disorder based on
any criteria (DSM, ICD)

Studies that include chronic patients, patients
with other mental illnesses that do not fall
under psychotic disorders, UHR, CHR, or
prodromal patients

Both affective and non-affective
psychotic disorders will be included.
There will be no restrictions on the age of
the sample.
Exposure &
Comparison

First episode psychosis with the
comparison of symptoms between
sexes/genders

Studies that do not compare symptoms of
psychosis between the sexes/genders

Outcome

Any study that evaluates symptoms of
early psychosis.

Studies that do not include symptoms of
psychosis

Study Design

Any observational study with quantitative
results.

Experimental or interventional studies, casereports, case-series, qualitative studies.

Time Frame

Must be published within 1990-2021

Publications prior to 1990.

No limits on follow up time will be
placed.
Other Exclusions

No limits on language or sample size will
be placed.

Non-peer reviewed articles will be excluded.
Abstracts will be excluded unless a
subsequent publication can be obtained.
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Appendix 3D: Symptom measurement tools across included studies (n=35)
Study ID, Author

Positive

Negative

Depression

Psychopathology

Functioning

Alcohol Use

Drug Use

1. Arnold et al. 64

SAPS*

SANS*

HDRS*

N/A

GAF*

N/A

N/A

2. Arranz et al.43

PANSS

PANSS

CDSS*

N/A

N/A

N/A

N/A

PANSS

PANSS

PANSS

N/A

GAF

Prevalence

Prevalence

SAPS

SANS

CDSS

BPRS

GAF

N/A

N/A

5. Barajas et al.

PANSS

PANSS

N/A

N/A

GAF

Prevalence

Prevalence

6. Bertani et al.67

N/A

N/A

PANSS*

N/A

N/A

N/A

N/A

7. Buck et al.68

SAPS

SANS

CDSS

N/A

SOFAS

N/A

N/A

PANSS

PANSS

PANSS

PANSS

N/A

N/A

N/A

CGI-S

CGI-S

CGI-S

N/A

N/A

PANSS

PANSS

N/A

PANSS

N/A

Prevalence (combined with
drug use)
N/A
N/A

N/A

N/A

N/A

BPRS

GAF

N/A

N/A

CGI-S

N/A

GAF

SAPS

SANS

CDSS

N/A

SOFAS

Prevalence (combined with
drug use)
Prevalence (combined with
drug use)
N/A
N/A

Sum of 4 items*

SANS

N/A

BPRS

SOFAS

N/A

N/A

PANSS*

PANSS*

CDSS*

PANSS*

GAF

Prevalence

Prevalence

BPRS

SANS

N/A

N/A

N/A

N/A

N/A

PANSS, SAPS

N/A

PANSS

SOFAS

N/A

N/A

N/A

N/A

GAF*

Prevalence

Prevalence

3. Austad et al.

40

4. Ayesa-Arriola et al.

65

66

8. Caton et al.

42

9. Chang et al.

39

10. Chen et al.69
11.Cocchi et al.

70

12. Cotton et al.44
13. Dama et al.71
14. Danaher et al.
15. Garcia et al.

72

73

16. Heitz et al.74
75

18. Køster et al.49

PANSS*

PANSS,
SANS
PANSS*

19. Lang et al. 76

PANSS

PANSS

N/A

PANSS

N/A

N/A

N/A

SAPS

SANS

CDSS

N/A

N/A

N/A

N/A

Criteria
checklist*
N/A

N/A

N/A

N/A

N/A

N/A

N/A

CDSS

N/A

N/A

Prevalence (combined with
drug use)
N/A
N/A

17. Hui et al.

20. Malla et al.77
78

22. Navarro et a. 79

Criteria
checklist*
N/A

23. Penney et al.80

SAPS

21. Mbewe et al.

24. Preston et al.

81

25. Pruessner et al.

82

26. Rapado-Castro et al.

Criteria
checklist*
Criteria
checklist*
SANS

PANSS

PANSS

N/A

PANSS

N/A

N/A

N/A

BPRS

BPRS

BPRS

N/A

GAF

N/A

Prevalence

PANSS

PANSS

N/A

PANSS

GAF

N/A

N/A

PANSS

PANSS

N/A

PANSS

GAF

N/A

N/A

PANSS*

PANSS*

N/A

N/A

N/A

N/A

Criteria
checklist*
PANSS

N/A

Criteria
checklist*
N/A

N/A

N/A

Prevalence

N/A

N/A

N/A

N/A
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27. Segarra et al.84
28. Suhail & Chaudry
29. Talonen et al.

86

30. Vila-Badia et al.87
31. Irving et al.

88

32. Cotton et al8.6
33. Häfner et al.

90

34. GonzaáezRodriguez et al.91
35. Thorup et al.38
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PANSS

N/A
Prevalence

Criteria
checklist*
CGI-S

Criteria
checklist*
N/A

Criteria
checklist*
CGI-BP

Criteria
Checklist*
CGI-BP mania

Criteria
checklist*
GAF

N/A

Prevalence

Prevalence

Prevalence

PSE,
CATEGO
BPRS

SANS, DAS

DAS

N/A

N/A

N/A

PSE

SANS

FCQ

BPRS

N/A

N/A

Prevalence

SAPS

SANS

N/A

N/A

GAF

N/A

N/A

Notes: SAPS = Scale for Assessment of Positive Symptoms, SANS = Scale for Assessment of Negative Symptoms, HDRS = Hamilton Depression Rating Scale,
GAF = Global Assessment of Functioning, PANSS = Positive and Negative Syndrome Scale, CDSS = Calgary Depression Scale for Schizophrenia, CGI-S = Clinical
Global Impressions Scale, SOFAS = Social Occupational Functioning Assessment Scale, SOPS = Scale of Psychotic-Risk Symptoms, BPRS = Brief Psychiatric
Rating Scale. * Means not available
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Appendix 3E: Positive and negative symptoms among included studies (n=32)
Study ID, Author

1. Arnold et al. 64
2. Arranz et al.43
3. Austad et al.40
4. Ayesa-Arriola et al.65
5. Barajas et al.66
7. Buck et al.68
8. Caton et al.42
9. Chang et al.39
10. Chen et al.69
13. Dama et al.71
14. Danaher et al.72
15. Garcia et al.73
16. Heitz et al.74
17. Hui et al.75
18. Køster et al.49
19. Lang et al. 76
20. Malla et al.77
21. Mbewe et al.78

22. Navarro et a. 79
23. Penney et al.80
24. Preston et al.81
25. Pruessner et al.82
26. Rapado-Castro et al.

Positive Symptoms
Women
Men
Mean
SD
Mean
AA: 12
AA:4
AA: 13
EA: 11
EA:4
EA: 11
24.5
6.2
26.81
14.1
3.2
14.9
14.48
4.34
13.84
25.69
8.51
25.75
16.54
16.82
14.43
17.6
8
19.1
4.2
0.9
4.2
15.82
4.6
16.26
34.63
16.62
34.04
8.77
4.7
8.74
(Median)
(Range)
9
7-17
10
14.4
3.58
12.8
5
9.3
4.5
18
19
22.8
5.3
28.7
2.12
2.7
2.7
(n)
(%)
(n)
Delusions: 27
60
84
Hallucinations:
73
87
33

SD
AA: 3
EA: 3
6.22
4.4
4.23
7.92
14.24
6.9
0.9
4.97
14.35
4.39
7-24
4.2
7.2
7.4
3.3
(%)
73
76

4.38
13.07
24.7
20.4

4.07
6.05
6.06
10.5

4.5
18.33
26.11
19.4

3.87
7.9
6.66
8.5

26.18
(n)
8
(n)
70
10.33
(n)
Delusions: 957
Halluc (aud/vis):
503
Halluc
(olfact/gust/tact):
162
Aggression: 802
Agitation: 879
Hostility: 477
Paranoia: 1122
5.5
(% only)
Non-specific
psychosis

7.23
(%)
12
(%)
100
4.95
(%)
76
40
12.9
63.8
69.9
37.9
89.2

25.71
(n)
10
(n)
36
11.51
(n)
1596
869
204
1494
1545
801
1917

7.2
(%)
13
(%)
100
4.78
(%)
76.3
41.5
9.8
71.4
73.9
38.3
91.6

0.7

5.8

0.8

Negative Symptoms
Women
Men
Mean
SD
Mean
AA: 13
AA: 5
AA: 13
EA: 13
EA: 5
EA: 13
16.29
8.63
15.23
18.6
7.6
19
6.43
5.8
6.83
27.06
12.2
27.42
21.68
13.82
23.09
13.8
6.3
14.3
2.5
1.3
2.7
15.89
5.23
16.8
22.39
13.07
25.64
24.82
13.43
26.35
(Median)
(Range)
14
7-28
14
20.6
16.2
27.2
9.7
4.3
10.9
19
21
18.5
5.5
23.3
5.3
4.5
6.7
(n)
(%)
(n)
15
33
37

SD
AA: 5
EA: 5
6.64
7.3
6.41
7.62
13.82
6.2
1.3
6.22
13.73
12.13
7-39
16.7
4.6
11.2
4.2
(%)
32

0.8
7.46
11.28
6.23
43.3

1.2
3.86
4.17
3.32
13.6

1.2
8.31
14.73
6.84
46.7

1.5
3.65
5.28
3.34
10.2

22.32
(n)
18

9.34
(%)
28

25.48
(n)
29

9.53
(%)
39

16.48
(n)
150

8.98
(%)
11.9

19.02
(n)
411

6.58
(%)
19.6
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27. Segarra et al.84
28. Suhail & Chaudry85
29. Talonen et al.86
30. Vila-Badia et al.87
31. Irving et al.88

32. Cotton et al8.6
33. Häfner et al.90

91.6

97.7

(% only)
Social
withdrawal
Anhedonia
Social
inattentiveness
1.1

56.5

77.9

62.6
32.6

76.6
47.6

34. Gonzaáez-Rodriguez
3.1
0.9
2.8
0.9
0.8
1.4
et al.91
35. Thorup et al.38
2.92
2.56
2.02
2.29
Note: All values are presented as means or SD unless otherwise specified. AA = African American, EA = European American

0.9
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Appendix 3F: Depressive symptoms among included studies (n=20)
Study ID, Author

Depressive Symptoms
Women

Men

Mean
AA: 23
EA: 22
(Median)
3
13.4

SD
AA: 10
EA: 9
(Range)
0-7.75
3.7

Mean
AA: 21
EA: 20
(Median)
2
12

SD
AA: 10
EA: 9
(Range)
0-6
3.6

7. Buck et al.68

2.24
3.41
3.92

3.2
1.78
4.5

3.08
2.92
2.5

4.01
1.77
3.98

8. Caton et al.42

12.1

3.9

10.8

4.9

9. Chang et al.39

2.6

1.3

2.2

1.4

12. Cotton et al.44

2.3

1.8

1.9

1.54

1. Arnold et al. 64
2. Arranz et al.43
3. Austad et al.40
4. Ayesa-Arriola et al.65
6. Bertani et al.67

13. Dama et al.

71

5.77

4.75

4.68

4.72

(Median)
1
1.9

(Range)
0-14
3

(Median)
1
1.5

(Range)
0-14
2.5

23. Penney et al.80

(n)
9
2.92

(%)
20
3.39

(n)
12
3.06

(%)
10
3.85

25. Pruessner et al.82

13.11

4.83

11.46

4.51

(n)
64
(n)
Worthless: 129
Anhedonia: 207
Low mood: 1162
Guilt: 426
Poor concentration: 817
Reduced appetite: 593
Low energy: 503
1.4

(%)
91.4
(%)
10.3
16.5
92.4
33.9
63.9
47.1
40
1.3

(n)
22
(n)
171
333
1874
576
1265
794
622
1.5

(%)
61.1
(%)
8.2
15.9
89.4
27.5
60.3
37.9
29.7
1.3

15. Garcia et al.73
21. Mbewe et al.78
22. Navarro et a. 79

29. Talonen et al.

86

31. Irving et al.88

32. Cotton et al8.6
33. Häfner et al.90

(% only)
Lack of interest in job
Underactivity during past
month
0.4

34. Gonzaáez-Rodriguez et
al.91
Note: All values are presented as means or SD unless otherwise specified
AA = African American, EA = European American

34.3
59.3
0.2

69.4
83.7
0.4

0.3
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Appendix 3G: General psychopathology symptoms among included studies (n=14)
Study ID, Author

General Psychopathology Symptoms
Women
Men
Mean
SD
Mean
AA: 24
AA: 8
AA: 22
EA: 23
EA: 8
EA: 24
64.82
13.1
64.62

1. Arnold et al. 64
4. Ayesa-Arriola et al.65
8. Caton et al.42
10. Chen et al.69
11.Cocchi et al.70
14. Danaher et al.72

SD
AA: 6
EA: 8
12.52

33.5
30.52
14.8
46.27

10.7
7.49
6.3
11.02

33.3
31.76
14.8
45.69

10.4
8.4
6.4
12.55

(Median)
23
23.3

(Range)
16-41
7.1

(Median)
26
22.6

(Range)
16-55
7.4

19. Lang et al. 76
24. Preston et al.81

36.3
27.92

5.8
6.9

50.5
31.9

13
10.38

26. Rapado-Castro et al.83

22.9

6.8

25.3

5.9

45.42

12.2

47.56

12.86

4.6

1.5

4.7

1.8

2.6

1.0

2.7

1.1

15. Garcia et al.73
17. Hui et al.75

27. Segarra et
32. Cotton et

al.84

al.89

34. González-Rodriguez et

al.91
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Appendix 3H: Functioning among included studies (n=16)
Study ID, Author

Functioning
Women

Men

3. Austad et al.40

Mean
32.3

SD
6.5

Mean
30.8

SD
7.7

4. Ayesa-Arriola et al.65

59.05

30.24

50.36

30.29

5. Barajas et al.66
7. Buck et al.68

35.36
63.27

15
18.5

34
61.98

9.66
17.04

11. Cocchi et al.70

45.6

14.3

45.3

10.4

al.44

33.6

9.2

31.4

10

44.04

13.79

39.98

12.79

14. Danaher at
15. Garcia et al.73

52.32
66

8.72
12.1

51.43
64

11.44
12.5

17. Hui et al.75

60.2

12.7

58.2

14.4

12. Cotton et
13. Dama et

al.71
al.72

18. Køster et

al.49

37

38

25. Pruessner et al.82
26. Rapado-Castro et al.83

31.44
32.3

9.16
16.8

29.43
36

8.71
14.6

27. Segarra et al.84
32. Cotton et al.89

40.11
33.5

17.49
9.1

37.35
29.7

14.78
10.1

35. Thorup et al.38

42.78

14.22

39.66

12.34
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Appendix 3I: Substance use symptoms among included studies (n=14)
Study ID, Author

3. Austad et al.40
5. Barajas et al.66
9. Chang et al.39
11. Cocchi et al.70
12. Cotton et al.44
15. Garcia et al.73
18. Køster et al.49
22. Navarro et al.79
25. Pruessner et al.82
30. Talonen et al.86
31. Irving et al.88
32. Cotton et al.89
33. Häfner et al.90
34. GonzálezRodriguez et al. 89

Substance Use
Women
Men
n
%
n
%

19
2
109

6

4

5.6
6
48.2

13

8.5

33
14
297

20

10

Alcohol Use
Women
Men
n
%
n
%
15
14.3
17
12.1
1
3.7
3
11.5

Drug Use
Women
Men
n
%
n
%
29
27.9 61
43.6
6
22
16
59

2
7

6.5
8

7
13

14.6
7

7
8

22.6
9

21
23

43.8
13

20

28.6

19

52.8

6

12.8

8

11.3

21
14
611
17

31.8
20
48.6
36.2
4.2
25.8

90
9
1570
39

63.4
25
74.9
54.9
14.8
46.4

9.2
12
68.3

25

14.1

8

26
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Appendix 3J: Meta-analysis of positive symptoms, with subgroup analysis by
measurement tool (n=21)

Notes: PANSS = Positive and Negative Syndrome Scale, SAPS = Scale for the Assessment of Positive Symptoms, CGIS = The Clinical Global Impression-Severity Scale, BPRS = Brief Psychiatric Rating Scale
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Appendix 3K: Meta-analysis of negative symptoms, with subgroup analysis by
measurement tool (n=21)

Notes: PANSS = Positive and Negative Syndrome Scale, SANS = Scale for the Assessment of Negative Symptoms,
CGI-S = The Clinical Global Impression-Severity Scale, BPRS = Brief Psychiatric Rating Scale
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Appendix 3L: Meta-analysis of depressive symptoms, with subgroup analysis by
measurement tool (n=12)

Notes: CDSS = The Calgary Depression Scale, PANSS = Positive and Negative Syndrome Scale, CGI-S/BP = The
Clinical Global Impression-Severity Scale/ Bipolar, BPRS = Brief Psychiatric Rating Scale, FCQ = Frankfurt
Complaint Questionnaire
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Appendix 3M Meta-analysis of general psychopathology with subgroup analysis by
measurement tool (n=12)

Notes: BPRS = Brief Psychiatric Rating Scale, PANSS = Positive and Negative Syndrome Scale, CGI-BP = The
Clinical Global Impression- Bipolar
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Appendix 3N: Meta-analysis of functioning, with subgroup analysis by
measurement tool (n=15)

Notes: GAF = Global Assessment of Functioning Scale, SOFAS = Social and Occupational Functioning Assessment
Scale
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Appendix 3O: Meta-analysis of substance use, with subgroup analysis by outcome
(n=13)
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Appendix 4P: The RECORD statement for observational studies using routinely
collected health data
Item
No.

STROBE items

RECORD items

1

(a) Indicate the study’s design with a
commonly used term in the title or the
abstract (b) Provide in the abstract an
informative and balanced summary of
what was done and what was found

RECORD 1.1: The type of data used should be
specified in the title or abstract. When possible, the
name of the databases used should be included.

Title and abstract

RECORD 1.2: If applicable, the geographic region
and timeframe within which the study took place
should be reported in the title or abstract.
RECORD 1.3: If linkage between databases was
conducted for the study, this should be clearly stated
in the title or abstract.

Introduction
Background rationale

2

Objectives

3

Methods
Study Design

4

Setting

5

Participants

6

Variables

7

Data sources/
measurement

8

Bias

9

Study size

10

Explain the scientific background and
rationale for the investigation being
reported
State specific objectives, including any
prespecified hypotheses
Present key elements of study design
early in the paper
Describe the setting, locations, and
relevant dates, including periods of
recruitment, exposure, follow-up, and
data collection
(a) Cohort study - Give the eligibility
criteria, and the sources and methods of
selection of participants. Describe
methods of follow-up
Case-control study - Give the eligibility
criteria, and the sources and methods of
case ascertainment and control selection.
Give the rationale for the choice of cases
and controls
Cross-sectional study - Give the
eligibility criteria, and the sources and
methods of selection of participants
(b) Cohort study - For matched studies,
give matching criteria and number of
exposed and unexposed
Case-control study - For matched
studies, give matching criteria and the
number of controls per case
Clearly define all outcomes, exposures,
predictors, potential confounders, and
effect modifiers. Give diagnostic
criteria, if applicable.
For each variable of interest, give
sources of data and details of methods of
assessment (measurement).
Describe comparability of assessment
methods if there is more than one group
Describe any efforts to address potential
sources of bias
Explain how the study size was arrived
at

RECORD 6.1: The methods of study population
selection (such as codes or algorithms used to
identify subjects) should be listed in detail. If this is
not possible, an explanation should be provided.
RECORD 6.2: Any validation studies of the codes or
algorithms used to select the population should be
referenced. If validation was conducted for this
study and not published elsewhere, detailed methods
and results should be provided.
RECORD 6.3: If the study involved linkage of
databases, consider use of a flow diagram or other
graphical display to demonstrate the data linkage
process, including the number of individuals with
linked data at each stage.

RECORD 7.1: A complete list of codes and
algorithms used to classify exposures, outcomes,
confounders, and effect modifiers should be
provided. If these cannot be reported, an explanation
should be provided.
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Quantitative
variables

11

Statistical methods

12

Data access and
cleaning methods

Linkage

Explain how quantitative variables were
handled in the analyses. If applicable,
describe which groupings were chosen,
and why
(a) Describe all statistical methods,
including those used to control for
confounding
(b) Describe any methods used to
examine subgroups and interactions
(c) Explain how missing data were
addressed
(d) Cohort study - If applicable, explain
how loss to follow-up was addressed
Case-control study - If applicable,
explain how matching of cases and
controls was addressed
Cross-sectional study - If applicable,
describe analytical methods taking
account of sampling strategy
(e) Describe any sensitivity analyses
..

..

Results
Participants

13

Descriptive data

14

Outcome data

15

Main results

16

(a) Report the numbers of individuals at
each stage of the study (e.g., numbers
potentially eligible, examined for
eligibility, confirmed eligible, included
in the study, completing follow-up, and
analysed)
(b) Give reasons for non-participation at
each stage.
(c) Consider use of a flow diagram
(a) Give characteristics of study
participants (e.g., demographic, clinical,
social) and information on exposures
and potential confounders
(b) Indicate the number of participants
with missing data for each variable of
interest
(c) Cohort study - summarise follow-up
time (e.g., average and total amount)
Cohort study - Report numbers of
outcome events or summary measures
over time
Case-control study - Report numbers in
each exposure category, or summary
measures of exposure
Cross-sectional study - Report numbers
of outcome events or summary measures
(a) Give unadjusted estimates and, if
applicable, confounder-adjusted
estimates and their precision (e.g., 95%
confidence interval). Make clear which
confounders were adjusted for and why
they were included
(b) Report category boundaries when
continuous variables were categorized
(c) If relevant, consider translating
estimates of relative risk into absolute
risk for a meaningful time period

RECORD 12.1: Authors should describe the extent
to which the investigators had access to the database
population used to create the study population.
RECORD 12.2: Authors should provide information
on the data cleaning methods used in the study.
RECORD 12.3: State whether the study included
person-level, institutional-level, or other data linkage
across two or more databases. The methods of
linkage and methods of linkage quality evaluation
should be provided.
RECORD 13.1: Describe in detail the selection of
the persons included in the study (i.e., study
population selection) including filtering based on
data quality, data availability and linkage. The
selection of included persons can be described in the
text and/or by means of the study flow diagram.
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Other analyses

17

Report other analyses done—e.g.,
analyses of subgroups and interactions,
and sensitivity analyses

Discussion
Key results

18

Limitations

19

Summarise key results with reference to
study objectives
Discuss limitations of the study, taking
into account sources of potential bias or
imprecision. Discuss both direction and
magnitude of any potential bias

Interpretation

20

Generalisability

21

Other Information
Funding

22

Accessibility of
protocol, raw data,
and programming
code

RECORD 19.1: Discuss the implications of using
data that were not created or collected to answer the
specific research question(s). Include discussion of
misclassification bias, unmeasured confounding,
missing data, and changing eligibility over time, as
they pertain to the study being reported.

Give a cautious overall interpretation of
results considering objectives,
limitations, multiplicity of analyses,
results from similar studies, and other
relevant evidence
Discuss the generalisability (external
validity) of the study results
Give the source of funding and the role
of the funders for the present study and,
if applicable, for the original study on
which the present article is based
..

RECORD 22.1: Authors should provide information
on how to access any supplemental information such
as the study protocol, raw data, or programming
code.
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Appendix Q: ICES Dataset Creation Plan
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Inclusion/
Exclusion
Criteria
Inclusion Criteria
Incident case of
nonaffective
psychotic
disorder
&
EMRPC
alignment

Data Sources

Variables/
Code Types

Window

Notes
(including algorithm details)

OMHRS
DAD
OHIP
NACRS

DSM4
ICD9
ICD10
OHIPDX

2005-2015

See Appendix A: OUT_PSY
1. DAD:
• Primary discharge
diagnosis (dxtype=M,
dx10code) of
schizophrenia,
schizoaffective disorder,
schizophreniform, or
psychosis NOS with a
valid IKN
• Restrict to the first date per
patient
• Use the discharge date in
DAD (DDATE) as the
index date
OR
2. OMHRS:
• Most responsible discharge
diagnosis
(AXIS1_DSM4CODE_DI
SCH1) of schizophrenia,
schizoaffective disorder,
schizophreniform, or
psychosis NOS in OMHRS
with a valid IKN
• Restrict to the first date per
patient
• Use the discharge date date
in OMHRS (DDATE) as
the index date
• Using
OMHRS_ADMISSION
database
OR
3. Ambulatory:
• All OHIP billings during
the accrual period with a
diagnostic code
(DXCODE) for
schizophrenia,
schizoaffective disorder,
schizophreniform, or
psychosis NOS with a
valid IKN, COMBINED
WITH:
• All emergency department
(ED) visits in NACRS (on
REGDATE) with a
diagnostic code
(DX10CODE) for
schizophrenia,

EMRPC.cohort
EMRALD.EMR_
MASTER
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Inclusion/
Exclusion
Criteria

Data Sources

Variables/
Code Types

Window

Notes
(including algorithm details)
schizoaffective disorder, or
psychosis NOS
• Exclude if there is no
evidence of two OHIP
physician billing claims or
two emergency department
(ED) visits with a
diagnostic code for
schizophrenia,
schizoaffective disorder, or
psychosis NOS occurring
in ANY 12 month period
(365 days)
• Restrict to the first date per
patient.
• Use SERVDATE in
OHIP or REGDATE
in NACRS from the
first ever claim as the
index date.
• If the OHIP servdate
and NACRS regdate
fall on the same date,
preferentially select
the OHIP observation
Restrict to the first episode:
1. In cases where a IKN
appears in more than one
cohort, use the date of the
first event as the index
date.
2. If the first date is the same
for more than one cohort,
preferentially select
Ambulatory > OMHRS >
DAD
EMRPC alignment:
First make
EMRALD.EMR_MASTER
unique by ikn and
d_ices_patient_id where
d_ices_patient_id^=. And
ikn^=’’.
Then pull IKNs from above
cleaned
EMRALD.EMR_MASTER
and join to EMRPC.cohort by
d_ices_patient_id.
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Inclusion/
Exclusion
Criteria

Data Sources

Variables/
Code Types

Window

Notes
(including algorithm details)
Join EMRPC.cohort from
above with IKN’s to
p0906.328.001 by IKN.

Exclusion Criteria
No primary care EMRPC
visits before
(Abstraction
index date
dataset)

Exposure

Sex

d_type
d_appointment
_date

Data Sources

RPDB

Clinical
Presentation

Variables/
Code Types

SEX

Before
index date

Window

Ref
date=Index
date

Include cases where
d_type=PN and
d_appointment_date < index
date

Reporting
Detail

Notes
(including
algorithm
details)

N (%)
female

Data Sources

Variables/
Code
Types

Window

Reporting
Detail

Age at psychosis
diagnosis

RPDB

BDATE

Ref
date=Inde
x date

Income quintile at
psychosis diagnosis

RPDB

INCQUIN
T

Index diagnosis

OHIP
NACRS
OMHRS
DAD

DSM4
ICD9
ICD10
OHIPDX

Ref
date=Inde
x date
Ref
date=Inde
x date

Mean (SD),
Median
(IQR),
N (%) each
category:
15-20, 2125, 26-30,
31-35
N (%) each
category,
missing
N(%) in
each
category
1.
Schizophre
nia
spectrum
disorder
2.
Psychosis
NOS

Notes
(including
algorithm
details)
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Clinical
Presentation

Data Sources

Variables/
Code
Types

Window

Reporting
Detail

Final Diagnosis

EMRPC.abstr
action

DX_FINA
L

Free text
input by FP

Number of Johns
Hopkins ADGs

DAD
OHIP
NACRS

ADG1-34
from
%GETAC
G

Ref
date=inde
x date, 1
year prior
to index
Ref
date=Inde
x date, 2
years
prior to
index

Number of primary
care help-seeking
visits

EMRPC.abstr
action

d_type,
d_appoint
ment_date

Rostered to FP

EMRPC.coho
rt

d_is_roste
r

Time on EMR

EMRPC.coho
rt

d_start_on
EMR

Ref
date=Inde
x date

EMRPC.abstr
action

FMCON

EMRPC.abstr
action

ALCHL

Ref
date=Inde
x date, 6m, 1 yr
prior to
index
Ref
date=Inde
x date, 6m, 1 yr
prior to
index

Ref
date=Inde
x date, 1
year prior
to index
Ref
date=Inde
x date

Mean (SD),
Median
(IQR),
N (%) each
category:
Low (< 5)
Medium (69)
High (10 or
more)
Mean (SD),
Median
(IQR),
Range
Flag
Yes/No
N(%) and
missing
Mean (SD),
Median
(IQR),
Range

Exposures
(signs/symptoms of
early psychosis
abstracted from
EMRs)
The family is
concerned/has
expressed worry
about the patient.

Excess use of
alcohol.

Flag
Yes/No
N(%)

Flag
Yes/No
N(%)

Notes
(including
algorithm
details)

d_type=PN
and
d_appointmen
t_date < index
date
d_is_roster=T
RUE then yes,
d_is_roster=F
ALSE then no.
Time on
EMR=Indexda
ted_start_onEM
R
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Clinical
Presentation

Data Sources

Variables/
Code
Types

Window

Reporting
Detail

Use of other street
drugs (i.e., other
than cannabis; e.g.,
inhalants,
hallucinogens,
cocaine and crack,
stimulants,
opiates).

EMRPC.abstr
action

DRGS

Ref
date=Inde
x date, 6m, 1 yr
prior to
index

Flag
Yes/No
N(%)

EMRPC.abstr
action

ARG

Flag
Yes/No
N(%)

EMRPC.abstr
action

ALNE

EMRPC.abstr
action

SLEEP

EMRPC.abstr
action

APPTT

EMRPC.abstr
action

DPRSN

EMRPC.abstr
action

CNCTN

EMRPC.abstr
action

RSTLS

Ref
date=Inde
x date, 6m, 1 yr
prior to
index
Ref
date=Inde
x date, 6m, 1 yr
prior to
index
Ref
date=Inde
x date, 6m, 1 yr
prior to
index
Ref
date=Inde
x date, 6m, 1 yr
prior to
index
Ref
date=Inde
x date, 6m, 1 yr
prior to
index
Ref
date=Inde
x date, 6m, 1 yr
prior to
index
Ref
date=Inde

Arguing with
friends and family.

Spending more
time alone.

Sleep difficulties.

Poor appetite.

Depressive mood.

Poor concentration.

Restlessness

Flag
Yes/No
N(%)

Flag
Yes/No
N(%)

Flag
Yes/No
N(%)

Flag
Yes/No
N(%)

Flag
Yes/No
N(%)

Flag
Yes/No

Notes
(including
algorithm
details)
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Clinical
Presentation

Data Sources

Variables/
Code
Types

EMRPC.abstr
action

TNSN

EMRPC.abstr
action

PLSR

EMRPC.abstr
action

WTCH

EMRPC.abstr
action

HALLU

EMRPC.abstr
action

SPC MNG

EMRPC.abstr
action

ODD
FLNG

EMRPC.abstr
action

ODD
SPCH

Tension or
nervousness

Less pleasure from
things (ie,
anhedonia)

Feeling people are
watching you or
giving you a hard
time for no reason

Feeling, hearing or
seeing things that
others cannot
Feeling that
everyday things
have a special
meaning just for
you
(delusions/ideas of
reference)
Feeling that
something odd is
going on that you
cannot explain (odd
beliefs or magical
thinking)
Odd manner of
thinking or speech
(disorganized/disco
nnected
thoughts/speech)

Window

Reporting
Detail

x date, 6m, 1 yr
prior to
index
Ref
date=Inde
x date, 6m, 1 yr
prior to
index
Ref
date=Inde
x date, 6m, 1 yr
prior to
index
Ref
date=Inde
x date, 6m, 1 yr
prior to
index
Ref
date=Inde
x date, 6m, 1 yr
prior to
index
Ref
date=Inde
x date, 6m, 1 yr
prior to
index

N(%)

Ref
date=Inde
x date, 6m, 1 yr
prior to
index
Ref
date=Inde
x date, 6m, 1 yr

Flag
Yes/No
N(%)

Flag
Yes/No
N(%)

Flag
Yes/No
N(%)

Flag
Yes/No
N(%)

Flag
Yes/No
N(%)

Flag
Yes/No
N(%)

Flag
Yes/No
N(%)

Notes
(including
algorithm
details)
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Clinical
Presentation

Data Sources

Variables/
Code
Types

EMRPC.abstr
action

INAPP
EMTN

EMRPC.abstr
action

ODD
BHVR

EMRPC.abstr
action

FAM
HIST

EMRPC.abstr
action

FUNCT

EMRPC.abstr
action

SYMPTO
MS
PS

Inappropriate affect

Odd behaviour or
appearance

First-degree family
history of psychosis

Increased stress or
deterioration in
functioning

Experienced a
psychosocial
stressor

Window

prior to
index
Ref
date=Inde
x date, 6m, 1 yr
prior to
index
Ref
date=Inde
x date, 6m, 1 yr
prior to
index
Ref
date=Inde
x date, 6m, 1 yr
prior to
index
Ref
date=Inde
x date, 6m, 1 yr
prior to
index
Ref
date=Inde
x date, 6m, 1 yr
prior to
index

Reporting
Detail

Notes
(including
algorithm
details)

Flag
Yes/No
N(%)

Flag
Yes/No
N(%)

Flag
Yes/No
N(%)

Flag
Yes/No
N(%)

Flag
Yes/No
N(%)

This is an item
from
“SYMPTOMS
” variable to
be separated
out and the
new variable
labelled “PS”
Note: the
specific
psychosocial
stressor was
also written
out in the
SYMPTOMS
textbox
variable – this
can be
disregarded. If
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Clinical
Presentation

Data Sources

Variables/
Code
Types

Window

Reporting
Detail

EMRPC.abstr
action

SYMPTO
MS
DAMB

Ref
date=Inde
x date, 6m, 1 yr
prior to
index

Flag
Yes/No
N(%)

EMRPC.abstr
action

SYMPTO
MS
BA

Ref
date=Inde
x date, 6m, 1 yr
prior to
index

Flag
Yes/No
N(%)

This is an item
from
“SYMPTOMS
” variable to
be separated
out and the
new variable
to be labelled
“BA”

EMRPC.abstr
action

SYMPTO
MS
Avolition

Ref
date=Inde
x date, 6m, 1 yr
prior to
index

Flag
Yes/No
N(%)

This is an item
from
“SYMPTOMS
” variable to
be separated
out and the
new variable
to be labelled
“avolition”

EMRPC.abstr
action

SYMPTO
MS
Alogia

Ref
date=Inde
x date, 6m, 1 yr
prior to
index

Flag
Yes/No
N(%)

This is an item
from
“SYMPTOMS
” variable to
be separated
out and the
new variable

Disorganized or
abnormal motor
behaviour

Blunted affect

Lack of
interest/decreased
motivation

Diminished speech

Notes
(including
algorithm
details)
“PS” is
present, or
there was a
psychosocial
stressor
written out,
flag that visit
as yes for
“PS”
This is an item
from
“SYMPTOMS
” variable to
be separated
out and the
new variable
to be labelled
“DAMB”
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Clinical
Presentation

Data Sources

Variables/
Code
Types

Window

Reporting
Detail

Notes
(including
algorithm
details)
to be labelled
“alogia”

EMRPC.abstr
action

SYMPTO
MS
AS

Ref
date=Inde
x date, 6m, 1 yr
prior to
index

Flag
Yes/No
N(%)

This is an item
from
“SYMPTOMS
” variable to
be separated
out and the
new variable
to be labelled
“AS”

EMRPC.abstr
action

SYMPTO
MS
PSL

Ref
date=Inde
x date, 6m, 1 yr
prior to
index

Flag
Yes/No
N(%)

This is an item
from
“SYMPTOMS
” variable to
be separated
out and the
new variable
to be labelled
“PSL”

EMRPC.abstr
action

SYMPTO
MS
HB

Ref
date=Inde
x date, 6m, 1 yr
prior to
index

Flag
Yes/No
N(%)

This is an item
from
“SYMPTOMS
” variable to
be separated
out and the
new variable
to be labelled
“HB”

EMRPC.abstr
action

SYMPTO
MS
PM

Ref
date=Inde
x date, 6m, 1 yr
prior to
index

Flag
Yes/No
N(%)

This is an item
from
“SYMPTOMS
” variable to
be separated
out and the
new variable
to be labelled
“PM”

EMRPC.abstr
action

SYMPTO
MS
PC

Ref
date=Inde
x date, 6-

Flag
Yes/No
N(%)

This is an item
from
“SYMPTOMS

Anxiety symptoms

Psychomotor
slowing

Hyperactive
behaviour

Poor memory

Psychosomatic
complaints
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Clinical
Presentation

Data Sources

Variables/
Code
Types

Window

Reporting
Detail

Notes
(including
algorithm
details)
” variable to
be separated
out and the
new variable
to be labelled
“PC”

m, 1 yr
prior to
index

EMRPC.abstr
action

SYMPTO
MS
Impulsivit
y

Ref
date=Inde
x date, 6m, 1 yr
prior to
index

Flag
Yes/No
N(%)

This is an item
from
“SYMPTOMS
” variable to
be separated
out and the
new variable
to be labelled
“impulsivity”

EMRPC.abstr
action

SYMPTO
MS
MLS

Ref
date=Inde
x date, 6m, 1 yr
prior to
index

Flag
Yes/No
N(%)

This is an item
from
“SYMPTOMS
” variable to
be separated
out and the
new variable
to be labelled
“MLS”

EMRPC.abstr
action

SYMPTO
MS
OCDS

Ref
date=Inde
x date, 6m, 1 yr
prior to
index

Flag
Yes/No
N(%)

This is an item
from
“SYMPTOMS
” variable to
be separated
out and the
new variable
to be labelled
“OCDS”

EMRPC.abstr
action

SYMPTO
MS
PIIMH

Ref
date=Inde
x date, 6m, 1 yr
prior to
index

Flag
Yes/No
N(%)

This is an item
from
“SYMPTOMS
” variable to
be separated
out and the
new variable
to be labelled
“PIIMH”

Impulsivity

Mania-like
symptoms

Obsessivecompulsive
disorder-like
symptoms

Poor insight into
mental health
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Clinical
Presentation

Data Sources

Variables/
Code
Types

Window

Reporting
Detail

EMRPC.abstr
action

SYMPTO
MS
SBSH

Ref
date=Inde
x date, 6m, 1 yr
prior to
index

Flag
Yes/No
N(%)

This is an item
from
“SYMPTOMS
” variable to
be separated
out and the
new variable
to be labelled
“SBSH”

EMRPC.abstr
action

SYMPTO
MS
IWPH

Ref
date=Inde
x date, 6m, 1 yr
prior to
index

Flag
Yes/No
N(%) and
missing

This is an item
from
“SYMPTOMS
” variable to
be separated
out and the
new variable
to be labelled
“IWPH”

EMRPC.abstr
action

SYMPTO
MS
CPCS

Ref
date=Inde
x date, 6m, 1 yr
prior to
index

Flag
Yes/No
N(%) and
missing

This is an item
from
“SYMPTOMS
” variable to
be separated
out and the
new variable
to be labelled
“CPCS”

EMRPC.abstr
action

SYMPTO
MS
FHBP

Ref
date=Inde
x date, 6m, 1 yr
prior to
index

Flag
Yes/No
N(%)

This is an item
from
“SYMPTOMS
” variable to
be separated
out and the
new variable
to be labelled
“FHBP”

EMRPC.abstr
action

SYMPTO
MS
LIQIDD

Ref
date=Inde
x date, 6m, 1 yr

Flag
Yes/No
N(%)

This is an item
from
“SYMPTOMS
” variable to
be separated

Suicidal
behaviour/selfharm

Issues with
personal hygiene

Current problems
with cigarette
smoking

Family history of
bipolar disorder in
a first-degree
relative

Low IQ/intellectual
or developmental
disability

Notes
(including
algorithm
details)
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Presentation

Data Sources

Variables/
Code
Types

Window

Reporting
Detail

Notes
(including
algorithm
details)
out and the
new variable
to be labelled
“LIQIDD”

prior to
index

EMRPC.abstr
action

SYMPTO
MS
ASD

Ref
date=Inde
x date, 6m, 1 yr
prior to
index

Flag
Yes/No
N(%)

This is an item
from
“SYMPTOMS
” variable to
be separated
out and the
new variable
to be labelled
“ASD”

EMRPC.abstr
action

SYMPTO
MS
PDPD

Ref
date=Inde
x date, 6m, 1 yr
prior to
index

Flag
Yes/No
N(%)

This is an item
from
“SYMPTOMS
” variable to
be separated
out and the
new variable
to be labelled
“PDPD”

EMRPC.abstr
action

SYMPTO
MS
BT

Ref
date=Inde
x date, 6m, 1 yr
prior to
index

Flag
Yes/No
N(%)

This is an item
from
“SYMPTOMS
” variable to
be separated
out and the
new variable
to be labelled
“BT”

EMRPC.abstr
action

SYMPTO
MS
SC

Ref
date=Inde
x date, 6m, 1 yr
prior to
index

Flag
Yes/No
N(%)

This is an item
from
“SYMPTOMS
” variable to
be separated
out and the
new variable
to be labelled
“SC”

Autism spectrum
disorder

A prior diagnosis
of any psychiatric
disorder

Borderline traits

Schizotypal
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Clinical
Presentation

Data Sources

Variables/
Code
Types

Window

Reporting
Detail

EMRPC.abstr
action

SYMPTO
MS
AB

Ref
date=Inde
x date, 6m, 1 yr
prior to
index

Flag
Yes/No
N(%)

EMRPC.abstr
action

SYMPTO
MS
PPA

Ref
date=Inde
x date, 6m, 1 yr
prior to
index

Flag
Yes/No
N(%)

This is an item
from
“SYMPTOMS
” variable to
be separated
out and the
new variable
to be labelled
“PPA”

Data Sources

Variables/
Code
Types

Window

Reporting
Detail

Notes
(including
algorithm
details)

RPDB

RURAL

EMRPC.abstr
action

FIRST
LANG
SPKN
LANG

Ref
date=Inde
x date
Ref
date=inde
x date

N (%) rural,
urban,
missing
English,
non-English

Aggressive
behaviour

Poor premorbid
adjustment

Other Concepts
Rurality (rural vs.
urban) at psychosis
diagnosis
Patient language

Notes
(including
algorithm
details)
This is an item
from
“SYMPTOMS
” variable to
be separated
out and the
new variable
to be labelled
“AB”
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